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Uric acid as a potential risk factor for cardiovascular and renal conditions has gained renewed 
attention. In this work we aimed to assess the associations between serum uric acid, metabolic 
syndrome, hypertension, renal dysfunction, cardiovascular events and mortality. 
In paper I, 6083 participants from Tromsø 4 were stratified according to body mass index. 
Endpoints were the metabolic syndrome and each component of the syndrome after seven 
years. Increased levels of baseline serum uric acid independently predicted development of 
hypertension and higher fasting glycemia in the overweight, but not in the normal-weight 
subjects. Baseline and longitudinal serum uric acid were both predictors of future metabolic 
syndrome.  
A prospective study that included 2637 participants who participated in Tromsø 4, 5 and 6 
was described in paper II. We assessed the associations between change in serum uric acid 
during follow-up, baseline serum uric acid and renal dysfunction (defined as albumin-
creatinine-ratio ≥1.13 mg albumin/mmol creatinine and/or estimated glomerular filtration 
rate < 60 ml/min/1.73 m2). Participants were stratified according to tertiles of change in serum 
uric acid between baseline and follow-up 13 years later. The upper tertile, compared to the 
two lower tertiles, had a doubled risk of renal dysfunction after 7 years, and after 13 years the 
odds ratio for renal dysfunction was 2.18. The risk of developing albumin-creatinine-ratio 
≥1.13 mg/mmol alone was also significantly increased.  An increase in baseline serum uric 
acid of 59 μmol/L gave an odds ratio of 1.16 for renal dysfunction after 13 years.  
In paper III, we included 5700 participants from Tromsø 4, and assessed the associations 
between serum uric acid and all-cause mortality after 15 years, and fatal or non-fatal 
myocardial infarction and ischemic stroke after 12 years. Serum uric acid was associated with 
all-cause mortality in men and women, even after adjustment for blood pressure, estimated 
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glomerular filtration rate, urinary albumin creatinine-ratio, drug intake and traditional 
cardiovascular risk factors. After the same adjustments, serum uric acid was associated with a 
31% increased risk of stroke in men. No independent association between increment in serum 
uric acid and myocardial infarction was observed. 
Our findings support the view that serum uric acid is associated with obesity, metabolic 
syndrome and hypertension, but also is a risk factor for cardiovascular and kidney disease, 
independently of these risk factors. Moreover, increasing values of serum uric acid over time 
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Mortality from coronary heart disease (CHD) and stroke has decreased substantially over the 
last 5- 10 years. [1] However, cardiovascular disease (CVD) is still the most common cause of 
death globally: The 2010 Global Burden of Disease study estimated that CVD caused 15.6 
million deaths worldwide. [1] When considering risk factors for CVD, a noticeable finding is 
that the geographic distribution of traditional risk factors is changing. The epidemic of 
overweight and obesity is increasing worldwide with considerable health and cost-
implications.[2, 3] While body mass index (BMI) and diabetes prevalence have increased in 
most countries and globally, [2, 4, 5] blood pressure (BP) has declined in some high-and 
middle-income regions. It has, however, remained unchanged or even increased in some low-
income countries.[6] Cholesterol has also declined in western countries, whereas values are 
increasing in East and Southeast Asia. [7] Smoking remains a notable contributor to non-
communicable diseases risk.[8, 9] The above-mentioned risk factors are currently being 
addressed by health authorities, and effort is made to implement preventive strategies. 
Nevertheless, although the risk factors listed above are important, there are still unexplained 
etiologic factors contributing to the mortality and morbidity associated with CVD, and there is 
still a need to identify novel modifiable risk factors. In addition, the risk factors associated 
with CVD are of importance not only for CVD, but also for other conditions, and especially 
renal diseases. The definition of the cardio-renal syndrome [10] has enhanced the 
awareness of the bidirectional interactions between kidney and heart diseases.[11] 
Chronic kidney disease (CKD) and CVD share many of the same risk factors. Moreover, the 
burden of CKD has become an increasing problem in a global perspective.[12-14] A 
systematic analysis of mortality in Lancet in 2013 stated that CKD is rising as a non-
communicable disease of global concern, but its importance has been neglected. Along with 
life style factors mentioned above, including change in diet and increasing obesity, a former 
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player has re-entered the scene. When exploring the literature concerning the etiology of CVD 
and CKD, the biologic substance uric acid (UA) has gained growing attention. [15]. Several 
researchers point on UA as a putative harmful substance in the etiology of CVD and CKD, 
but studies have yielded conflicting results. [16-20] 
In this work, the role of UA in various conditions has been explored. We have studied the 
associations of serum uric acid (SUA) with development of hypertension, other components 
of the metabolic syndrome (MetS), renal dysfunction (RD), CVD and mortality. In the 
population based Tromsø Study, SUA has been measured repeatedly. Thus, in contrast to 
many other studies, we were able to look at the impact of change in SUA level during a period 
of time, in addition to the baseline value.  
 
1.1 Background 
UA is generated during the breakdown of purines from DNA, RNA, ATP and cAMP to 
hypoxanthine. Further breakdown to xanthine and UA (2,6,8-trihydroxypurine, C5H4N4O3,) 
(Figure 1) is done mainly in the liver by the action of the enzyme xanthine oxidoreductase 
(XOR), which can exist in two forms, xanthine dehydrogenase (XDH) or xanthine oxidase 
(XO). [19] The enzyme is mostly in its XDH form, but can be transformed into XO by 
proteolytic cleavage or oxidation. Reactive oxygen species are a by-product of the reaction 
from hypoxanthine to xanthine and from xanthine to UA. [21, 22] In humans, UA is the final 
product, whereas in most mammals UA is further degraded into 5-hydroxyisourate by the 
enzyme uricase, eventually producing allantoin, which is highly soluble and easily 
excreted.[23] Due to a series of mutational silencing events in its gene during hominoid 
evolution, humans, and their great ape relatives, do not have a functional uricase.[24] This 
results in urate levels that are much higher in humans; averaging between 240-366 µmol/L 
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(4.0-6.0 mg/dL) compared to other mammals that generally have SUA in the range 30-120 
µmol/L (0.5–2.0 mg/dL).[17] 
Most circulating UA is freely filtered by the kidney, with roughly 90 % of the filtered load 
being reabsorbed in the proximal tubule.[25] UA is also subjected to tubular secretion, and 
thus the renal handling of UA is complex. A smaller proportion of UA, approximately 1/3, is 
excreted into the intestine and further metabolized by resident gut bacteria.[26] UA is a weak 
diprotic acid (has two dissociable protons), and at the physiologic pH (7.4), a proton 
dissociates from ~99% of UA molecules, and thus most UA is present in the extracellular 
fluid as the anion urate. Because the ratio of urate to UA in the circulation remains constant 
with constant pH, the terms urate and uric acid are often used interchangeably to refer to the 
total pool of UA, dissociated and un-dissociated.[26] Due to the high concentration of sodium 
in the extracellular compartment, urate is mainly present as monosodium urate, with a low 
solubility limit (about 380 μmol/L). [27] When urate solubility is exceeded, monosodium 
urate crystals develop in and around the joints. This crystal formation is responsible of acute 
gout and, over time, of chronic gout; but only a small proportion of people with 
hyperuricemia will develop clinical gout.[15] 
 
 
Hypoxanthine + H2O + O2 ←→  Xanthine + H2O2 
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          Xanthine + H2O + O2 ←→ Uric acid + H2O2 
Figure 1 
UA is accumulated in the body due to increased production, such as with cell death, intake of 
alcohol or a purine rich diet.[16, 28-30] Also a diet with excess sugar increases the SUA level, 
because the sugar-component fructose causes increased UA production. Otherwise, 
accumulation of UA is caused by decreased elimination, which is the case in impaired renal 
function or with the use of diuretics or certain other medications. 
The biologic action of UA is a paradox in the way that although it is considered the strongest 
circulating anti-oxidant of the body, [20] it can be pro-oxidative under certain conditions. [31, 
32] In recent research there has been focus not only on crystal development as a cause of 
disease.  Apparently, also a modest rise in SUA may be harmful. In the process of generating 
UA, XO also generates reactive oxygen species. It has been hypothesized that harmful 
mechanisms are initiated during this process, either through UA generation with increased 
oxidative stress, or through elevated UA per se. [15, 17-20, 33] 
 
 
1.1.1 Historical perspectives 
A state-of-the-art review has looked carefully at the role of UA from its discovery in the early 
1800s, when it was considered a causal factor not only for gout, but also for a variety of 
cardiovascular and renal conditions, until its “requiem” as a risk factor was celebrated in a 
review article in Kidney International in 1986.[20] The fact that hyperuricemia was 
considered a risk factor was not surprising, as natural history showed that 25–50% of gouty 
subjects had hypertension, 75% were obese, 25% died with kidney failure, and 90% 
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developed cardiac disease, making gout the most important cardiovascular risk factor then 
known.[20]  
Described by Hippocrates during the Golden Age of Greece, gout was originally a disease of 
the affluent, primarily observed in middle-aged men of the wealthy upper class (“the Patrician 
malady”).[34] Being “disease of kings and king of diseases,” gout has afflicted kings 
(including Alexander the Great and Henry VIII), statesmen (including Benjamin Franklin), 
artists (including Voltaire), and scientists (including Isaac Newton, Charles Darwin, and 
Leonardo da Vinci). Chronic lead intoxication from contamination of wine and food has also 
been implicated in the epidemics of gout that affected both the Roman Empire and Victorian 
England, since lead toxicity impairs the ability of the kidney to excrete UA. In 1897, in his 
presidential address to the American Medical Association, Dr. Davis wrote, “High arterial 
tension in gout is due in part to uric acid or other toxic substances in the blood which increase 
the tonus of the [renal] arterioles.[35] 
By the mid-1900s, however, the causal nature of UA in these conditions was questioned, as it 
was recognized that the association of gout with CVD might simply reflect that gout and 
cardiovascular complications had similar risk factors (obesity, kidney disease, etc.). This was 
addressed in epidemiologic studies by asking whether SUA was an independent risk factor for 
cardiovascular and renal disease, while controlling for other known risk factors.   
Some studies continued to find that SUA was an independent risk factor; however, others did 
not. The inconclusiveness of the data, the supposition that soluble UA was biologically inert 
or even an antioxidant, and the finding that the increase in SUA might be secondary to either 
a decrease in renal function or the presence of hyperinsulinemia, all led to the conclusion that 
SUA most likely was not a true cardiovascular or renal risk factor. In the 1980s, SUA was 
removed from some of the common laboratory panels, markedly reducing the available 
epidemiologic data on SUA in otherwise healthy persons and those suffering from CVD.[36] 
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The move was made because serious side effects from the urate lowering drug allopurinol 
were observed in patients with asymptomatic hyperuricemia, with an intention to reduce the 
risk of harm to these patients. 
 
1.1.2 Definitions of hyperuricemia 
Currently, no general consensus exists regarding how to define hyperuricemia. In an article 
where different definitions of hyperuricemia were explored, the authors claimed that such 
discrepancies preclude comparison of data from different studies and may be seen as a barrier 
to the understanding of gout by physicians and patients. [37] SUA is generally lower in 
women than in men, but in both genders distributions grossly follow Gaussian curves. [38-40]    
Thus, a statistical definition of hyperuricemia is possible with a SUA concentration lying 
more than two standard deviations (SD) above the mean. This definition, which gives higher 
normal values for males than for females, is being used in most laboratory reports. [40] As 
gout is known to follow crystallization of monosodium urate, a physicochemical definition of 
hyperuricemia as a concentration above the saturation point, (which is about 380 µmol/L) 
may also seem logical. In this view, there is no obvious reason to differentiate men from 
women. [40] In our studies we chose to define hyperuricemia in the same way as in the U.S 
National Health and Nutrition Examination Survey (NHANES) 2007–2008, as SUA ≥ 417 
μmol/L (7 mg/dL) in men and ≥339 μmol/L (5.7 mg/dL) in women.[41]      
 
1.2 Distribution of elevated SUA in the population 
Epidemiologic studies show that mean SUA levels in men have increased gradually from the 
1920s to the 1970s, from less than 210 µmol/L to 360-390 μmol/L.[18] High levels of SUA is 
prevalent in the general population; in the NHANES 2007-08 cohort hyperuricemia was 
present in 22 % of women, and 21 % of men.[41] In the US, the prevalence of gout more than 
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doubled between 1969 and 1985, [42] may have increased further over the past two decades, 
and parallels a significant increase in the prevalence of hyperuricemia.[41]  
Age does not significantly affect SUA levels in men, but in women the levels are 
progressively higher in the older age groups. The rise occurs gradually, with the greatest 
increment in the decade between forty and fifty, an effect presumably related to the 
menopause. [37] Pre-menopausal women tend to have lower levels than men, probably 
because of the uricosuric effect of estrogens.[38] 
In an article exploring the distribution of SUA levels worldwide, [39] the authors have only 
investigated men because of what they call « the confounding effect of estrogen in pre-
menopausal women.» Examination of these data shows that e.g. most Pacific Island 
populations and their proposed ancestral populations have higher occurrence of 
hyperuricemia, and a high mean SUA level of 390 µmol/L (6.5 mg/dL). While some of this 
variation could relate to differences in lifestyles and environment, the authors think that 
ancestry also is a likely contributing factor: it is feasible that SUA concentrations may have 
been positively selected under certain environmental conditions. Environment also has an 
effect on SUA levels; a number of studies have been sampled from both urban and rural 
cohorts from within the same population to help understand the effects of urbanized 
living.[43-50] Higher SUA levels were generally observed in those inhabiting an urban 
environment. In general, living in an urban environment exacerbates the tendency towards 
elevated SUA levels, concomitant with the increased consumption of foodstuffs such as 
sugar-sweetened beverages and alcohol that increase urate.[28, 51, 52] However, the fact that 
even those living rurally and with more traditional lifestyles in Polynesia have high rates of 
hyperuricemia, compared to other populations worldwide, suggests a genetic predisposition, 
leading to the variability which we see in modern populations globally.[39, 53] It has been 
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suggested that the higher SUA levels in this population may explain their higher frequency of 
obesity and diabetes compared to other peoples throughout the world.[54]  
A few studies have explored racial and ethnical differences also in other parts of the world, 
and found evidence for genetic influence of SUA levels in different racial/ethnic groups. [55, 
56] In one study, lower SUA was found among African than Caucasian men, [57] whereas 
others have found higher SUA in black compared to white persons. [16] However, the first 
study was performed in South Africa, and the other in the US. 
 
1.3 Uric acid as a risk factor for the MetS 
MetS is a constellation of interrelated risk factors that increases the risk of CVD and type 2 
diabetes.[58] 
There are several definitions of the MetS. Among the most frequently used definitions is the 
revised National Cholesterol Education Program’s Adult Treatment Panel III (NCEP-ATP III) 
criteria published by the American Heart Association. Any three (or more) out of five of the 
following criteria constitute the diagnosis of MetS: [59] 
•Increased waist circumference (≥ 88 cm in women and ≥ 102 cm in men) 
•Elevated triglycerides (≥ 1.7 mmol/L or the use of lipid-lowering drugs)  
•Reduced high density lipoprotein (HDL)-cholesterol (< 1.30 mmol/L in women and < 1.03 
mmol/L in men)  
•Elevated BP (≥ 130 mmHg systolic BP, ≥ 85 mmHg diastolic BP or antihypertensive drug 
treatment)  
•Elevated fasting glucose (glucose ≥ 5.6 mmol/L or on treatment for elevated glucose)  
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The prevalence of MetS increased significantly between NHANES 1988-1994 and NHANES 
1999-2006, and one of the main reasons for this was the increase in abdominal obesity. [60]      
The worldwide increase in the prevalence of hyperuricemia is considered to be directly related 
to the increasing incidence of obesity and the MetS in developing countries, [61] as well as in 
developed countries.[62] Increased SUA concentration correlates strongly with obesity and 
the MetS. [63, 64] Historically, the elevated level of SUA observed in MetS has been 
attributed to hyperinsulinemia, since insulin reduces renal excretion of UA. [18, 65] However, 
hyperuricemia often precedes the development of hyperinsulinemia, [18, 65, 66] obesity,[67] 
and diabetes.[66, 68, 69] Hyperuricemia may also be present in the MetS in people who are 
not overweight or obese.[18] MetS occurs in up to 76 % of patients with gouty arthritis.[70, 
71]  
It has been suggested that UA may cause MetS by promoting a state of insulin resistance. It is 
well known that insulin stimulates glucose intake in skeletal muscle also via increased blood 
flow to these tissues through a nitric oxide (NO)-dependent pathway. UA decreases levels of 
NO, reduces arterial dilatation and blocks the action of insulin, resulting in increased insulin 
resistance and hyperinsulinemia.[72] The relationship may also be a result of the stimulating 
effect of insulin on urate reabsorption in the proximal tubule.[67]  
 
1.4 Uric acid as a risk factor for hypertension  
Numerous studies have reported that hyperuricemia carries an increased risk for development 
of hypertension independent of other risk factors.[18, 35] The strength of the relationship 
between SUA level and hypertension decreases with increasing patient age and duration of 
hypertension, suggesting that UA may be most important in younger subjects with early-onset 
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hypertension.[18, 35] The controversy over the role of UA in hypertension stems from the lack 
of plausible mechanisms and its overlap with other more conventional risk factors for 
hypertension such as renal disease, diabetes and obesity.[36] However, in 2001, animal 
experiments by Johnson and colleagues suggested a plausible cause-and-effect-relationship. 
Using a rat model of pharmacologically induced hyperuricemia, they showed that increased 
SUA levels resulted in hypertension within 2 weeks. Early hypertension was completely 
reversible with urate reduction, but prolonged hyperuricemia resulted in irreversible sodium-
sensitive hypertension that became UA independent. These mechanistic studies supported a 
UA-mediated activation of the renin-angiotensin system, a system with rapid onset that can also 
be rapidly controlled, followed by a more gradual alteration of renal microvascular geometry 
and sodium handling that resulted in chronic salt-sensitive hypertension. The renal 
microvascular disease was shown to occur independently of hypertension and clinically 
resembled the renal arteriosclerosis lesion of human hypertension.[18, 20, 65] The observation 
that the microvascular changes still developed, even when BP was controlled by a diuretic, 
coupled with the demonstration of direct effects of UA on endothelial cells and vascular 
smooth-muscle cells, suggested that UA could cause microvascular disease independently of 
hypertension. [18] In experiments with cultured vascular smooth-muscle cells, UA was able to 
induce cellular proliferation, inflammation, oxidative stress, and activation of the local renin–
angiotensin system.[18] However, these findings were made in animals. 
Concerning human biology and SUA, an interesting renal biopsy study was performed in 2013: 
[73] In a cross-sectional study of 167 CKD patients, it was found that as the SUA level 
increased, the degree of renal arteriolar hyalinosis and wall thickening worsened. These results 
suggest that hyperuricemia may be related to renal arteriolar damage in patients with CKD. 
There are a few randomized controlled trials (RCT)s that explore the effect on BP when 
decreasing SUA with medication. Of special interest are the RCTs where hyperuricemic 
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adolescents with an early stage of hypertension were randomized to SUA lowering agents 
versus placebo.[74] Thirty adolescents were randomized to allopurinol or placebo for four 
weeks; 70 % of the participants were obese. BP in the allopurinol-group decreased 
significantly compared to the placebo group. It is not possible to state whether the effect of 
allopurinol to lower BP was explained by the lowering of SUA, or by inhibition of XO with 
reduced production of reactive oxygen species.  
To explore this further, the authors performed a similar trial in 2012.[75]  Prehypertensive obese 
adolescents were randomized to allopurinol, the uricosuric drug probenecid or placebo. 
Subjects treated with either allopurinol or probenecid exhibited a significant reduction in BP, 
and therefore the effect was probably due to reduction in UA rather than to XO inhibition. This 
suggests that at least in adolescents with prehypertension, UA may cause increased BP that can 
be mitigated by urate lowering therapy. An additional surprising effect was that participants on 
urate lowering therapy ceased to gain weight. The authors summarize that allopurinol and 
probenecid treatment resulted in similar BP responses, which implicates UA as the biochemical 
mediator of increased BP.[75]      
To explore change in BP after allopurinol initiation in older patients, data from the UK Clinical 
Practice Research Datalink was used in a propensity-matched design.[76] Data were extracted 
for patients with hypertension aged >65 years who were prescribed allopurinol with readings 
of BP pretreatment and during treatment. Data from comparable controls were extracted. The 
change in BP in patients with stable BP medication was the primary outcome and was compared 
between groups. Three hundred sixty-five patients who received allopurinol and 6678 controls 
were included. BP fell in the allopurinol group compared with controls. There was a trend 
toward greater fall in BP in the high-dose allopurinol group, but change in BP was not related 
to baseline UA level. The authors conclude that allopurinol use is associated with a small fall 
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in BP in adults and that further studies of the effect of high-dose allopurinol in adults with 
hypertension are needed.[76] 
When exploring the literature of the associations between SUA, hypertension and the MetS, 
fructose intake has been extensively debated.  Fructose raises UA levels rapidly via activation 
of the fructokinase pathway in hepatocytes. Fructokinase consumes ATP, leading to an 
increased load of intracellular purines requiring metabolism and disposal through XO-mediated 
metabolism, ending in UA.[36]  
Through the 18.century there was an increasing production of sugar from sugar beets.[77] 
Sucrose is a disaccharide of glucose and fructose, produced from these plants, and used as 
table sugar and food additive. As one of the components of sucrose is fructose, increased 
intake of sugar, will lead to increased fructose-consumption. Although fructose is present in 
significant quantities in fruits, the largest single source of fructose in the diet is added sugars 
consumed in desserts, candies and sweetened beverages. [78]  
Globally, the main source of fructose is sucrose, which constitutes >90% of the energizing 
sweeteners used in the world. [79] However, in the U.S it is common to use so called high 
fructose corn syrup,  generated from maize, which is easily available, and less expensive than 
sugar.  
Experimental data support a link between fructose intake, hyperuricemia, and increases in BP. 
Rats fed with high doses of fructose developed hyperuricemia, hypertension and a metabolic-
like syndrome with renal hemodynamic and histologic changes, very similar to those observed 
with hyperuricemia. Treating these rats with the XO inhibitors allopurinol or febuxostat, 
lowered UA levels and prevented these changes. [18] In humans, one of the most important 
problems with excess fructose intake seems to be increased de novo lipogenesis, and thus 
altered blood lipid profile seems to be the most prominent feature. [79]   
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Sharp criticism to the fructose hypothesis has also been raised.[80] It has been claimed that 
too much research money has been spent on this issue when trends show that fructose 
consumption actually is declining, while obesity is still increasing. Moreover, the animal 
studies have been criticized for the fact that the rats were fed with very high doses of fructose. 
 In a Norwegian review on the role of fructose, the author concluded that evidence is lacking 
that a normal consumption of fructose (approximately 50–60 g/day) increases the risk of 
atherosclerosis, type 2 diabetes, or obesity more than consumption of other sugars. [79] 
However, a high intake of fructose, particularly if combined with a high energy intake in the 
form of glucose/starch, may have negative health effects via de novo lipogenesis. The author 
concluded that more studies are needed that explore the impact of  normal fructose 
consumption.[79] 
To summarize, a major research effort has been made to describe the associations between 
SUA, hypertension and MetS, but there are still areas of significant uncertainty. SUA as a risk 
factor for hypertension has been studied extensively. However, there is a need to gain 
knowledge about differences between subgroups, including different age groups and various 
categories of obesity. As focus on individually targeted strategies is growing in modern 
medicine, and currently also is used in antihypertensive treatment, options may expand when 
the impact of SUA is further explored. Large RCTs in adolescents as well as other populations 
of various risk may reveal important knowledge. In addition, we still need observational data 
to further explore associations of importance, such as the possible impact of SUA on long-term 
dysmetabolic changes. 
 
1.5 Uric acid as a risk factor for kidney disease. 
CKD has emerged as a global health problem of epidemic proportions over the last few 
decades.[81] The prevalence of end-stage renal disease (ESRD), and the number of patients on 
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renal replacement therapy, is steadily increasing, and these patients have a 10-fold mortality 
rate.[82] Impaired kidney function increases the risk not only for ESRD and dialysis, but also 
for CVD. [83, 84] 
In 2002, the US National Kidney Foundation Kidney Disease Outcomes Quality Initiative 
clinical practice guidelines defined CKD as glomerular filtration rate (GFR) <60 mL/min per 
1,73 m2 for ≥ 3 months,[13] and proposed a classification scheme based on GFR.[85] Later 
studies have shown that albuminuria also has an important effect on outcomes.[86] This made 
the Kidney Disease Improving Global Outcomes (KDIGO) Work Group on Evaluation and 
Management of Chronic Kidney Disease to include albuminuria in the revised 2012 
classification.[13] 
Even mild abnormalities in measures of renal structure and function are associated with 
increased risk of kidney failure or development of complications in other organ systems, 
especially CVD.[12] 
In the article in Lancet cited above, [12] the authors describe CKD in relation to the MetS. It is 
known that hypertension and diabetes are important risk factors for ESRD. However, why some 
individuals with MetS develop albuminuria and decrease in GFR before the development of 
hypertension or diabetes is not known. One possibility is that underlying mechanisms, such as 
endothelial dysfunction and oxidative stress, might drive both kidney damage and the MetS. 
[12] Some authors think that diets high in added sugars (which implicates excess fructose) 
might have a key role in development of MetS and kidney disease by elevating UA. [87] Mild 
kidney disease was induced in rats fed a high fructose diet.[88] Low-grade systemic 
inflammation, which is present in these disorders, could also result in changes in adipokines 
and other substances that can affect glomerular capillary wall function.[89].  
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Hyperuricemia has been recognized as a risk factor for the incidence and progression of CKD, 
although studies have reported conflicting results (Table 1). [82, 90-100] A major 
methodological problem concerning UA and kidney function is that of reverse causality. UA is 
eliminated mainly through the kidneys, and raised UA levels could be a consequence rather 
than a cause of reduced kidney function.  
In 2009, the result of a large study focusing on risk factors for ESRD was published.[93] As 
many as 177570 individuals from an integrated health care delivery system in Northern 
California were followed for 25 years. The 2 most potent risk factors were proteinuria and 
excess body weight. However, the study also identified several novel risk factors for ESRD, 
among them a higher level of SUA. Large prospective observational studies show that increased 
SUA levels predict the development and progression of CKD in various populations (Table 
1).[14, 82, 92-94, 98, 101-107] Studies have also suggested that UA may be an independent 
predictor of the development of microalbuminuria.[70, 108]    
Before SUA lowering drugs became available, more than 50% of patients with gout had some 
renal insufficiency, and nearly 100% had renal disease at autopsy.[18] The kidney lesions in 
patients with gout are characterized by advanced arteriolosclerosis, glomerulosclerosis, and 
interstitial fibrosis, often with the presence of urate crystals in the outer medulla. The presence 
of such urate deposits gave rise to the name "gouty nephropathy" for this condition. However, 
the hypothesis that renal injury was caused by the deposition of urate crystals seemed 
incomplete, considering that the crystal deposition was focal, and thus unlikely to explain the 
diffuse nature of the disease. Crystals may also be found in normal kidneys in the absence of 
inflammation. Furthermore, the most characteristic findings, which are advanced 
arteriolosclerosis and glomerulosclerosis, are indistinguishable from those observed with 
longstanding hypertension or age-related glomerulosclerosis, may simply reflect the fact that 
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most patients with gout have hypertension and are older. Consequently, for the past 30 years 
there has been a widespread belief that UA is unlikely to be a risk factor for renal disease. [18] 
However, both experimental and clinical studies suggest the possibility that an elevated level 
of SUA itself can lead to kidney disease without the deposition of UA crystals.[109, 110] 
Experimental studies in rats have shown that elevated SUA levels can cause de novo kidney 
disease as well as accelerate existing kidney disease.[109, 110] In rats, the mechanism of injury 
appears to be related to the development of preglomerular arteriolar disease that impairs the 
renal autoregulatory response, thereby causing glomerular hypertension. [18, 111]  
As mentioned earlier, a human cross-sectional study has assessed the association between SUA 
and changes in renal tissue. [73] In patients with CKD it was found that with higher SUA levels, 
the degree of renal arteriolar hyalinosis and wall thickening worsened. 
In a recently published meta-analysis that included fifteen unique cohorts, the investigators 
demonstrated a positive association between SUA levels and the risk of CKD, defined as 
eGFR <60 mL/min/1.73 m2 at the follow-up examination, in middle-aged patients, 
independent of established metabolic risk factors. The risk for CKD increased by 20 % per 59 
µmol/L (1 mg/dL) rise in SUA. They conclude that future randomized, high-quality RCTs,  
are warranted to determine whether lowering SUA levels is beneficial in CKD.[14] 
Recent studies suggest that lowering levels of UA in patients with hyperuricemia may slow 
progression of renal disease. A study showed that the treatment of asymptomatic 
hyperuricemia in patients with CKD stage 3 resulted in delayed disease progression. Among 
patients treated with allopurinol, 16 % progressed to ESRD, compared to 46 % in the control 
group. [112]  
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Another RCT showed that treatment of asymptomatic hyperuricemia with allopurinol 
improved eGFR. [113]   
To summarize, despite of the methodological challenges with reverse causality, SUA has been 
increasingly assessed as a risk factor for CKD in epidemiological studies. Some RCTs have 
also been performed, although they are small in design. There is a need for high-quality RCTs 
to replicate the findings that decreasing SUA may be beneficial for CKD patients, and prevent 
CKD in those having hyperuricemia. In addition, in most of the epidemiological studies 
performed so far, CKD has been defined on the basis of GFR alone. By including albuminuria 
in the definition, also subtle renal damage may be captured. Also, most studies assess SUA as 





Table 1. Overview of epidemiologic studies assessing uric acid as a risk factor for kidney disease 
Authors, year, 
country 









et al. 2005, 
Thailand 
Employees of the 
Electric Generation 
Authority 
3499 12 years 
1985 
Age, sex, BMI, smoking, eGFR, 
proteinuria, systolic and diastolic BP, 
diabetes, cholesterol 
MDRD formula not 
validated in their population. 
No s-albumin 
OR: 1.82 (1.12, 2.98) for decreased 
kidney function for SUA in fourth 
quartile compared to first quartile 
Chonchol et al. 
2007, US 
General population > 
65 in the 
Cardiovascular Health 
Study 
5808 6.9 years 
1989 
Age, sex, BMI, 
antihypertensives,allopurinol, 
diuretics, creatinine, systolic and 
diastolic BP HDL triglycerides, 
carotis intima thickness, hemoglobin, 
race 
Measurement of albuminuria 
were not available 
No increased risk for incident 
CKD, but for prevalent CKD 




21475 7 years 
1990 
Age, sex, eGFR, antihypertensive 
drugs, waist circumference, HDL, 
cholesterol, glucose, triglycerides, 
BP, exercise 
MDRD formula, not gold 
standard, may have led to 
underestimation of GFR 
Slighly elevated SUA (>7-8.9 
mg/dL, OR:1.75 for incident CKD. 
Elevated SUA ˃ 9 mg/dL, OR: 3.12 
Risk for incident CKD increased 
roughly linearly with UA to level of 
6-7 mg/dl in women and 7-8 mg/dl 
in men; above these levels, the risk 
increased rapidly. 










13338 8.5 years 
1987 
Age, gender, race, diabetes, systolic 
BP, hypertension, CVD, left 
ventricular hypertrophy, smoking, 
alcohol use, education, lipids, 
albumin, hematocrit, baseline eGFR 
 
No information on baseline 
proteinuria and allopurinol 
use 
Each 1 mg/dl increase in UA 
increased risk of CKD 7-11 % 
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Hsu et al 2009, 
US 
Volunteered for health 
checkups 
177570 25 years 
1964 
Age, sex, diabetes, level of 
education, race, BMI, elevated BP, 
creatinine level,urine dipstick levels 
of protein, glucose, and hemoglobin 
Exposures were only 
assessed once 
No assess variables such as 
illicit drug use, use of 
analgesic medications, or 
circulating inflammatory 
markers. 
Higher UA quartile conferred 2.14-
fold increased risk of ESRD over 
25 years 
Sonoda et al. 
2011, Japan 
General population 7078 5 years 
2001 
Age, sex, BMI, SBP, lipids 
hemoglobin, smoking,  
Health checkup program 
Albuminuria not available 
Longitudinal and baseline SUA 
increased the OR for CKD 




2544 26 years 
1976 
Age, sex, BMI, hematocrit, 
creatinine, glucose,   lipids,    fasting 
glucose ASAT, serum globulins, 
diabetes medication thyroxin, 
bilirubin  proteinuria 
Low number of events.  
Might have lost some cases 
that were never hospitalized 
Hazard ratios (HR)s 
2.87 (p = 0.003) for acute renal 
failure  
2.14 (p < 0.001) for chronic renal 
failure 
Zhang L et al. 
2012, China 
General population 1410 4 years 
2004 
Age, sex, BMI smoking, 
hypertension diabetes (yes/no), 
albuminuria (yes/no) and baseline 
eGFR  
UA was measured only 
once at baseline, and have 
no information of UA-
lowering drugs. 
Renal decline 
(baseline eGFR <90 and eGFR 
decreased ≥20% during 4 years, 
or eGFR decreased ≥20% during 
4 years and eGFR <60 at the 
second visit 
OR 1.19 (per 1 mg/dL increase 
in SUA; 95% CI 1.04–1.38). 
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Age, sex, BMI, hypertension, 
diabetes,  cholesterol, smoking, 
alcohol drinking exercise 
Recruited from individuals 
who went to the health 
promotion center to check 
their health status.  
Increased risk of CKD when  
comparing the highest and 






1.6 Uric acid as a risk factor for CVD and mortality 
The relationship between SUA and CVD is not clear. Some epidemiologic studies have 
reported a relationship between SUA and several cardiovascular conditions [16, 114-119] 
whereas others have observed no such link. [120-123] The studies have to a varying extent 
been able to adjust for important confounders.  
The epidemiologic studies that have failed to discern any independent association of 
hyperuricemia with CVD are far fewer than those who show such a link.[33] In an article 
considering medical implications of hyperuricemia, it was claimed that the studies of healthy 
individuals in which correlation between hyperuricemia and cardiovascular mortality was not 
found, tended to have a low number of events per-person-years.[124] 
RCTs assessing the effect of SUA lowering treatment have so far been sparse, but a few 
warrant some comment. 
The Losartan Intervention For Endpoint reduction (LIFE) study demonstrated that SUA 
reduction was correlated with an improved cardiovascular outcome in patients treated with 
losartan compared with those taking atenolol.[68] Losartan decreases urate reabsorption in the 
proximal tubule and produces sustained reduction in SUA levels.[125]The LIFE study 
demonstrated that 29 % of the benefit of losartan was attributable to the decrease in SUA levels 
during treatment, even after accounting for diuretic use and renal function. The finding suggests 
a role of SUA lowering in prevention of CVD. However, the LIFE Study was not primarily 
designed to assess the impact of SUA lowering, and the study depended on multivariable 
analysis to come to this conclusion. Unforeseen confounding might have been present with one 
of the many other effects of losartan.[126]  
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Concerning stroke, the paradoxical effects of UA are sharply illustrated by two RCTs. In a 
study published in 2014, 206 women and 205 men with acute ischemic stroke were 
randomized to treatment with UA or placebo in combination with thrombolysis.[127] The 
primary outcome was the rate of excellent outcome at 90 days, defined according to a 
modified Rankin scale, which measures degree of disability. In women, but not in men, the 
administration of UA reduced infarct growth: 42 % of women had an excellent outcome 
compared to 29 % in the placebo group. On the other hand, another RCT published in 2014, 
evaluated the effect of one-year treatment with allopurinol in eighty patients with ischemic 
stroke or transitory ischemic attack (TIA).[128] Allopurinol lowered central BP and reduced 
carotid intima thickness progression compared with placebo in patients with recent ischemic 
stroke and TIA. These studies had opposite approaches, one study was assessing treatment 
during the acute stroke event, and the other investigated treatment in the post-stroke phase. 
Still, these examples illustrate an UA effect paradox. 
Another interesting RCT was published in 2010. Allopurinol was compared with placebo in 65 
patients with chronic stable angina pectoris and angiographically documented coronary artery 
disease. [129] Participants were randomized to high-dose allopurinol or placebo for 6 weeks 
before crossover. High dose allopurinol significantly improved the primary endpoint, which 
was the time to ST depression during a standard exercise test, and the secondary endpoints, 
which were total exercise time and time to chest pain, suggesting that endogenous XO activity 
contributes somehow to exercise-induced myocardial ischemia. 
A study with data from the United Kingdom Clinical Research Practice Datalink assessed 
whether allopurinol treatment in hypertensive patients >65 years could be associated with less 
strokes and cardiac events over a 10-year period, using a propensity-matched design. [130] It 
was found that the patients who had been prescribed allopurinol regularly had a lower 
occurrence of stroke and cardiac events than those who did not receive allopurinol. The 
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apparent benefit was driven by treatment at higher doses. The authors conclude that RCTs, 
particularly at doses of ≥300 mg daily, are needed to further explore whether allopurinol 
improves cardiovascular outcomes in patients with hypertension. 
The studies above show that SUA lowering therapy may be a promising therapeutic option in 
CVD, however, more trials confirming these findings are needed.  
Despite growing evidence in the literature that SUA is a true risk factor for CVD, this is still 
controversial, and asymptomatic hyperuricemia is not an indication for prophylactic 
treatment. The epidemiological studies in this field are many, but with varying ability to 
adjust for confounders. Many of the studies also lack generalizability as they have assessed 
selected groups. In addition to the need for RCTs assessing the effect of SUA lowering 
therapy, large epidemiological studies with ability to control for confounders like eGFR and 





2.  AIMS OF THE THESIS  
The overall aim of this project was to study the longitudinal association between SUA and 
traditional risk factors, as well as to assess whether SUA is an independent risk factor for 
cardiovascular and renal disease in a general population. 
 
More specifically, the aims of the thesis were as follows: 
 
1. To investigate the association between SUA and the development of hypertension and 
MetS in a large population-based cohort stratified for overweight. 
 
2. To assess whether hyperuricemia is associated with development of impaired renal 
function. We also aimed to assess whether increase in SUA over time is a risk factor 
for kidney damage, defined as albuminuria and/or a decrease in eGFR after 7 and 13 
years of follow-up. 
 
3. Explore whether SUA is an independent risk factor for myocardial infarction, 





3. STUDY POPULATION AND METHODS 
3.1 The Tromsø Study 
The Tromsø study is a population based cohort study with six repeated health surveys in the 
municipality of Tromsø, Northern Norway. The study was initiated in 1974 as a response to 
the high cardiovascular mortality rate in Northern Norway, particularly in men. The study was 
gradually expanded to include many other diseases, such as rheumatism, venous 
thromboembolism, neurological and mental diseases, skin diseases, stomach and bowel-
related diseases, cancer, osteoporosis and kidney disease. The Institute of Community 
Medicine at the UiT, The Artic University of Norway is responsible for the study, and the 
seventh wave is currently ongoing. In Tromsø 4 in 1994/95, all inhabitants aged 25 and above 
were invited, and 27158 (77% of the eligible population) participated. All participants aged 
55-74 years, and 5-10 % random samples of the other birth cohorts older than 24 years (10542 
individuals), were invited to a second visit with extensive examination including blood and 
urine testing after 4-12 weeks. Attendance rate was 76 % (7965 individuals). Subjects who 
had previously taken part in the second visit in Tromsø 4 were eligible for a second-visit 
examination in Tromsø 5 (2001/02), and 5939 participated (85% of the eligible). Tromsø 6 
was run in 2007/08. Subjects eligible for the second visit in Tromsø 6 were first-visit 
participants aged 50–62 or 75–84 years, a 20% random sample aged 63–74 years and subjects 
who had attended the second visit of Tromsø 4. Out of the 11 484 subjects who were eligible, 
7307 (64%) attended. [131]  About 80 % of the participants in Tromsø 6 had previously 
attended Tromsø 4.  
In all three papers of the current thesis, data from the Tromsø Study were used, but with some 
differences. In paper I, participants from Tromsø 4 and Tromsø 5 were included. The study 
population consisted of 6160 participants at baseline, of whom 5496 also attended Tromsø 5. 
In paper II, data from all three surveys (Tromsø 4, 5 and 6) was used. This paper describes a 
cohort of 2637 participants who had SUA measurements in all three surveys. In paper III, 
34 
participants from Tromsø 4 were included. The participants were followed until the 
occurrence of the clinical endpoints myocardial infarction and ischemic stroke and/or death 
after 12 and 15 years, respectively. In this cohort, participants with known previous 
myocardial infarction, ischemic stroke or diabetes were excluded, and our cohort consisted of 
5700 participants with SUA measurements in Tromsø 4. 
 
3.2 Measurements and clinical variables 
Each survey used a self-administered questionnaire with information about medication, 
presence of diabetes and CVD, smoking habits and physical activity (Appendix I). 
Anthropometric and BP measurements were standardized, and performed by trained 
personnel. Height and weight were measured with participants wearing light clothing and no 
shoes. BP was recorded with an automatic device (Dinamap Vital Sign Monitor 1846 
Critikon). Three measurements were made at one-minute intervals after 2 minutes resting, and 
the mean of the two final recordings was used. According to the NCEP-ATPIII definition of 
MetS, hypertension was defined as systolic BP ≥ 130 mmHg and/or diastolic BP ≥ 85 mmHg 
and/or current use of antihypertensive medication in article I. In article II and III, the BP cut-
offs used to define hypertension were higher, systolic BP ≥ 140 mm Hg and/or diastolic BP 
≥90 mmHg combined with the use of antihypertensives. Physical activity was classified as 
active (> 1 hour physical activity with prominent sweating or breathlessness per week) or 
inactive (all others). Smoking habits were classified as current smokers or not (all others).  
For logistic reasons, all blood samples were non-fasting. SUA was measured by photometry 
with COBAS® instruments (Roche diagnostics, Switzerland) using an enzymatic colorimetric 
test, the uricase/ PAP method. Reference values were140-340 μmol/L (2.4-5.7 mg/dl) for 
females and 200-415 μmol/L (3.4-7.0 mg/dl) for males. 
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In paper I, we classified participants according to the revised NCEP-ATPIII criteria for the 
MetS. Because our data lacked fasting blood samples, we modified the definition of elevated 
triglycerides and elevated glucose in paper I. For the definition of elevated fasting glucose, we 
set the cut off at ≥ 7.8 mmol/L if time since last meal was less than four hours, and at ≥ 5.6 
mmol/L if time since last meal was at least four hours. For the definition of elevated 
triglycerides, we set the cut-off at ≥ 2.28 mmol/L if time since last meal was less than four 
hours, as non-fasting triglyceride levels are on average 20% to 30% higher than fasting 
levels.[132] If time since last meal was ≥4 hours, the cut-off was 1.7 mmol/L. 
In Tromsø 4 and 5, plasma creatinine was analysed by a modified Jaffe reaction, but since 
creatinine-based estimation of GFR is better validated for enzymatic creatinine measurements, 
111 plasma samples from the 1994/95 survey and 142 samples from Tromsø 5 were thawed 
and reanalysed with an enzymatic method (Modular P/Roche). Values were fitted to a linear 
regression model, and recalibrated creatinine values were calculated for all participants. In the 
sixth Tromsø study, serum creatinine was analysed on a Hitachi Modular model using an 
enzymatic method that has been standardized against isotope dilution mass spectroscopy 
(CREA Plus, Roche Diagnostics, GmbH, Mannheim,Germany). eGFR was calculated 
according to the CKD-EPI equation: eGFR = 141 × min(SCr/k,1)
a × max(SCr/k,1)
-1.209 × 
0.993age × ([1.018 if female] and × [1.159 if black]) where SCr is serum creatinine (mg/dL), k 
is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min 
indicates the minimum of SCr/k and max indicates the maxiumum of SCr/k).[133]. 
Three separate samples of morning spot urine from three consecutive days were collected, and 
fresh (non-frozen) samples were analysed within 20 hours. Urinary albumin and creatinine 
were analysed using kits from ABX Diagnostics, Montpellier, France. Albumin-to-creatinine 
ratio (ACR) in mg/mmol was calculated for each day and the mean of all three was used in 
the analyses in article II and III. Serum total cholesterol was analysed by enzymatic 
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colorimetric methods with commercial kits (CHOD-PAP; Boehringer Mannheim, Mannheim, 
Germany). In paper II the dichotomous variable RD (Renal Dysfunction) was defined using a 
modification of the 2012 KDIGO CKD classification.[134] We chose the “high normal” 
albuminuria stage (ACR≥1.13 mg/mmol) as the cut-off value for pathological urinary albumin 
excretion. Participants with eGFR<60 ml/min/1.73 m² and/or ACR≥1.13 mg/mmol were 
considered to have RD. 
 
 
3.3 Endpoint assessment 
Paper III describes the prospective associations of SUA with clinical endpoints. Three 
different endpoints, first-ever non-fatal or fatal myocardial infarction, first-ever non-fatal or 
fatal ischemic stroke and all-cause mortality were evaluated. 
The Tromsø Study Cardiovascular Disease Registry was responsible for assessment and 
validation of the cardiovascular endpoints. Adjudication of hospitalized and out-of-hospital 
events was done for each event by thorough review of hospital and out-of-hospital records, 
autopsy reports and death certificates. Event ascertainment followed a detailed protocol. For 
myocardial infarction, established diagnostic criteria were used to evaluate symptoms, 
electrocardiogram, myocardial biomarkers and/or autopsy findings, and all events that were 
classified as definite, probable or possible myocardial infarctions were included as endpoints 
in article III. Stroke was defined according to the WHO definition, only ischemic strokes were 
included. [135]. 
Individuals who had died or emigrated from Tromsø were identified through the Population 
Registry at Statistics Norway. The national 11-digit identification number allowed a linkage 
to the National Population Registry and ensured a complete follow-up status for all-cause 
mortality until Nov 30th, 2010 (15 years). Since the cardiovascular endpoint registry was 
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complete only until December 31th, 2007, follow-up time for myocardial infarction and 
ischemic stroke from screening was 12 years. Data were censored for emigration, and, in case 
of myocardial infarction and stroke, for deaths from other causes. 
 
3.4 Statistical analyses 
Covariates in each study were selected on the basis of previous scientific knowledge. We 
chose variables that are known or suspected confounders, mainly demographic variables, 
traditional cardiovascular risk factors, life style factors, relevant drug use and eGFR.  
In article I and II logistic regression analyses were performed with MetS and different 
components, and RD as dependent variables, respectively. The analyses were adjusted for the 
variables mentioned above, and in in addition for baseline GFR in article II. In article III, 
SUA was categorized into gender-specific tertiles. Crude and age-adjusted incidence rates 
were calculated as events per 1000 person years at risk. Cox proportional hazard models were 
used to investigate associations of SUA with cardiovascular outcomes and mortality, 
calculated per 1 SD (87 μmol/L) increase in baseline SUA, in unadjusted, age-adjusted and 
multivariable adjusted analyses. The proportional hazard assumption was checked by visual 
inspection of the -log-log survival curves.  Non-linear effects were also explored in fractional 
polynomial regression models.  
P values < 0.05 were considered statistically significant. Most analyses were run using SPSS 
software version 15.0 (SPSS, INC, Chicago, Illinois) and 21 (IBM SPSS Statistics for 
Windows Armonk, NY). Fractional polynomial regression models were performed with 
STATA/MP 12.1 (Stata Corp LP, College Station, Texas).  
 
38 
3.5 Ethical considerations 
The Regional Committee for Medical Research Ethics approved the study, and all participants 




4.1 Paper I 
 
Overweight modifies the longitudinal association between uric acid and some components of 
the metabolic syndrome: The Tromsø Study 
 
In this prospective cohort study, we assessed whether baseline and longitudinal change in 
SUA was a risk factor for development of MetS and its individual components. We included 
2920 women and 2792 men who had SUA measured in Tromsø 4. The participants were 
stratified according to BMI. Endpoints were MetS and each component of the syndrome after 
seven years, according to the revised NCEP-ATP III definition. Multiple logistic regression 
analyses showed that higher baseline SUA was associated with higher odds of developing 
hypertension in overweight subjects (BMI ≥ 25 kg/m2; OR per 59 µmol/L SUA increase 1.44, 
95% confidence interval (CI) = 1.17-1.78, p = .001.) This association was not significant in 
normal-weight subjects (BMI < 25 kg/m2), and p for interaction between overweight and SUA 
was .044. Overweight also modified the association between baseline SUA and the 
development of elevated glucose (p for interaction = .039). However, SUA was a strong 
predictor of MetS in all subjects (OR per 59 µmol/L SUA increase 1.32, 95% CI 1.21-1.44, p 
< .001). Furthermore, longitudinal SUA change was independently associated with the 
development of MetS in all subjects (OR per 59 µmol/L SUA increase over seven years 1.36, 
95% CI 1.22-1.51, p < .001). To summarize, increased levels of baseline SUA independently 
predicted the development of hypertension and higher fasting glycemia in the overweight, but 
not the normal-weight subjects. Baseline SUA was a predictor of future MetS, and 
longitudinal increase in SUA over seven years was also associated with the development of 
MetS in all subjects.  
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4.2 Paper II 
 
Uric acid is associated with microalbuminuria and decreased glomerular filtration rate 
in the general population during 7 and 13 years of follow-up: The Tromsø Study 
 
In a prospective cohort study which included 2637 men and women who participated in 
Tromsø 4, 5 and 6, we assessed the associations between change in SUA during follow-up, 
baseline SUA and RD. Participants were stratified according to tertiles of change in SUA 
between baseline (1994/95) and follow-up 13 years later (upper tertile: SUA increasing group, 
two lower tertiles: SUA non-increasing group). After excluding participants with RD at 
baseline, we found that SUA increasers, compared to SUA non-increasers, had a doubled risk 
of RD after 7 years (OR 2.00, (95 % CI 1.45- 2.75)). OR for RD in SUA increasers after 
13 years was 2.18 (95 % CI 1.71- 2.79). The risk of developing ACR ≥1.13 mg/mmol alone 
was significantly increased after 13 years (OR 1.43 (95 % CI 1.09-1.86)), but not after 7 years 
(OR 1.30 (95 % CI 0.90- 1.89)). An increase in baseline SUA of 59 μmol/L gave an OR for 
RD after 13 years of 1.16 (95 % CI 1.04-1.29). In conclusion, an increase in SUA during 




4.3 Paper III 
 
Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general 
population: a gender specific analysis from The Tromsø Study 
In this prospective cohort study, we included 2696 men and 3004 women who participated in 
Tromsø 4, and examined the association of SUA with three different endpoints: all-cause 
mortality after 15 years, fatal or non-fatal myocardial infarction and ischemic stroke after 12 
years. In total, 1433 deaths, 659 myocardial infarctions and 430 ischemic strokes occurred 
during follow-up. In multivariable Cox regression analyses adjusted for several traditional and 
non-traditional risk factors for CVD, a 1 SD (87 μmol/L) increase in SUA gave and increased 
risk of all-cause mortality in both genders (HR men; 1.11 (95% CI 1.02-1.20), women; 1.16 
(1.05-1.29). HRs and 95% CI for stroke were 1.31 (1.14-1.50) in men and 1.13 (0.94-1.36) in 
women. No independent associations were observed with myocardial infarction. 
In conclusion, SUA was associated with all-cause mortality in men and women, even after 
adjustment for BP, eGFR, urinary ACR, drug intake and traditional cardiovascular risk 







5.1 Methodological considerations 
 
5.1.1 Bias 
In epidemiology, discussion of bias can be simplified under the headings of a) selection (of 
population), b) information (collection, analysis and interpretation of data), and c) 
confounding, although, this phenomenon is sometimes considered as separate from bias. [136] 
 
5.1.2 Selection bias 
Selection bias is present if the estimated association among those selected differs from the 
associations among the eligible.[137] Some define selection bias as a situation where subjects 
are allowed to select the study group they want to be in. [138] In our study, participants were 
selected if they were inhabitants of an area and belonged to a certain age group. However, 
self-selection may be a problem, and could threaten external validity; the attenders in health 
surveys tend to be more educated and have a healthier life style than non-attenders.[139] In 
Tromsø 4, all inhabitants of the municipality of Tromsø ≥25 years were invited, and the 
attendance rate (77%) is considered high among epidemiological studies. This enhances the 
probability that the study population is representative of the general population. In studies of 
randomly sampled populations, the non-response is typically 30-40 per cent, and sometimes 
much higher.[136] Still, in Tromsø 4, almost one out of four did not attend, and in Tromsø 6, 
the attendance rate was even lower; 63 %. The attendance rate was low among the age group 
younger than 40, and at the age of 80 and older.[131] As it is likely that non-responders differ 
from responders, we cannot rule out that his may have influenced the results. In addition, the 
vast majority of the participants were Caucasians, which limits applicability to other 
ethnicities.[131] Paper II presents follow-up data of participants who met at three different 
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waves of the Tromsø Study during 12-14 years of follow-up time. Compared to the 
participants who attended one or more of the follow-up surveys, the participants who only 
attended the Tromsø 4 Study (1994/95) had a less favorable cardiovascular risk profile. They 
were older, had higher SUA level, lower eGFR, higher ACR, higher BMI, and higher 
cholesterol. There were also more participants with hypertension, known diabetes, and a 
history of myocardial infarction and stroke in this cohort. All in all, the study population was 
healthier than the source population. 
 
5.1.3 Information bias 
Information bias occurs when the variable of interest, i.e. the main exposure, covariates or the 
outcome, is measured with measurement error. Measurement error in categorical variables is 
often referred to as misclassification. [140]    
Measurements can have both random and systematic errors, [141] and both may cause biased 
effect estimates.[140, 142] However, random errors where there are enough observations 
usually produce a correct estimate of the average value. 
These biases are also named non-differential or differential biases where differential bias 
relates to systematic error and non-differential is random and consequently affects all 
subgroups equally.[136]  






SUA   
The association between SUA and outcomes was investigated in all three articles. SUA was 
measured by photometry with COBAS® instruments (Roche diagnostics, Switzerland) using 
an enzymatic colorimetric test. Several thousand measurements were performed in each wave 
of the Tromsø Study by trained laboratory staff at the University Hospital, and at the 
Metabolic research lab, UiT. There is no reason to believe that these measurements have been 
exposed to systematic error. However, random errors are likely, but due to the high number of 
participants, this has probably not affected the results. 
 
Change in SUA  
In article I and II, change in SUA was used as an exposure variable. In article I, increase in 
SUA was associated with MetS. In article II, change in SUA was assessed as an exposure 
with decreased eGFR as an outcome. We have tested for inter-correlation between these two 
variables, which was satisfactory low. However, we know that increased SUA values are 
observed with increasing GFR, probably partly because of decreased renal elimination of UA. 
In this manner, the assessment and analyses of these variables are problematic and must be 
interpreted with caution. However; change in SUA is associated with increased ACR as well, 
which strengthens the finding that increasing SUA is associated with renal dysfunction.  
When constructing two groups of a change variables, the phenomenon “regression to the 
mean” may represent a problem. This phrase was first described by Francis Galton (1822-
1911), where regression means “to revert to” or “return to”. This bias comes from the 
observation that measurements that initially lie at the extremes tend to move nearer the 
average on subsequent measurements. As described by the epidemiologist Bhopal: “in 
essence, the cause is random error.”[136] In our case, if some SUA values were very low or 
very high, they would tend to be closer to the mean at the next measurement. This means that 
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some participants will be misclassified as having very high or very low SUA. In this setting, a 
mean value of these two measurements may better represent the true value. Consequently, in 
our study we cannot rule out the possibility that some subjects have been misclassified. 
 
Hypertension  
In article I hypertension defined as BP ≥ 130/85 mmHg was one of the main outcomes. There 
could be some problems related to this biological endpoint as exemplified by Bhopal [136]: 
“BP varies from moment to moment in response to activity, in a 24-hour cycle with lowered 
pressure in the night. There is no readily available estimate of the true summary.” As a 
compromise, BP was taken under standard conditions, measured three times, and the average 
of the two last readings was used. The value is useful in clinical practice and epidemiology, 
but it is not an accurate summary. Long-term recordings of BP over several days (ambulatory 
BP) were not available. It is conceivable that this measurement error mainly would be 
random, but systematic error could not be ruled out. If for instance a BT-cuff used by the 
overweight participants read differently from the cuff used by lean participants, this could 
introduce bias. 
 
Serum glucose and triglycerides  
 For logistic reasons, non-fasting blood samples were obtained in the Tromsø Study, which 
may be problematic for the interpretation of serum glucose and triglyceride values. In article 
I, modifications were made when classifying both variables most affected by the lack of 
fasting blood samples, namely glucose and triglycerides. For elevated fasting glucose we have 
maintained the cut-off of ≥ 5.6 mmol/L for the subjects with at least four hours since last 
meal, and for the persons with less than four hours since last meal, we have set the cut-off at ≥ 
7.8 mmol/L, the cut-off used for impaired glucose tolerance in oral glucose tolerance tests.  
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However, it is likely that misclassifications may have occurred in both directions, as level of 
glucose not only depends on time since last meal, but also on what has been eaten and 
physical activity. This is a source of bias that we are unable to compensate for, and a major 
limitation when exploring metabolic associations. On the other hand; requesting participants 
to attend in a fasting state would probably had a major negative impact on the attendance rate. 
 
Creatinine values and eGFR   
In article II eGFR˂ 60 ml/min/1.73 m² was used as an outcome in combination with ACR, 
and eGFR was a covariate in article I and III. Creatinine values from Tromsø 4 and 5 were 
recalibrated as described, because a possible drift was observed between the originally 
measured values. In spite of the recalibration, a certain degree of inaccuracy cannot be ruled 
out.  
Because serum creatinine concentration depends on muscle mass, equations to estimate GFR 
have been developed with the goal of overcoming this limitation. The Cockcroft-Gault [143] 
and Modification of diet in renal Disease (MDRD) equations have been extensively 
used,[144] but  the first tends to overestimate GFR [145] and MDRD tends to underestimate 
GFR in a kidney-healthy population.[146] Thus, healthy persons may erroneously have been 
categorized as having CKD.[146] The CKD-EPI equation, which was published in 2009, 
performs better than the MDRD for GFR >60 ml/min/1.73 m², and approximately the same 
when GFR is less than 60 ml/min/1.73 m². Therefore, we have chosen this equation for eGFR. 
However, since the CKD-EPI equation also is based on serum creatinine, GFR will be biased 
in people with reduced muscle mass.[147]  
eGFR aims to estimate the true GFR from serum creatinine, sex and age, but in the word 
estimate the limitation is already stated: it is not an exact measurement. In the cross-sectional 
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Renal Iohexol Clearance Survey in Tromsø 6 (RENIS-T6), GFR was measured by iohexol 
clearance and estimated by creatinine or cystatin C in a middle-aged cohort from the general 
population.[148] The aim of the study was to explore the validity of using eGFR as a proxy 
for mGFR in studies of CVD risk. The results suggested that eGFR partially depends on 
factors other than the true GFR. The possibility of residual confounding from these factors in 
studies of GFR and cardiovascular risk in persons with a GFR close to the normal range 
cannot be ruled out. Thus, the authors conclude that estimates of cardiovascular risk 
associated with small changes in eGFR must be interpreted with caution. 
. 
Urinary ACR   
In article II, ACR ≥1.13 mg /mmol was the second component of the main outcome RD. 
Albumin assessed in a 24-hour urine sample is the gold standard measurement for 
albuminuria. However, long-time urine collection is impractical and subject to significant 
error due to incompleteness and/or inadequate timing. Therefore, substitute measures 
including albumin concentration and ratio of albumin to creatinine concentrations (ACR) 
from a spot urine sample, have been validated and is considered satisfactory and preferable. 
[149, 150] By dividing the urinary albumin concentration by the creatinine concentration, 
differences in urinary dilution are corrected for, since creatinine excretion rate is nearly 
constant in each individual. However, again we are dependent on creatinine that, as described 
above, is influenced by the amount of muscle mass, gender, age and ethnicity.[151] Still, a 
strength in our study is the use of fresh urine samples, thus avoidance of prolonged storage, 
freezing and thawing  that reduce the value of albuminuria for endpoint prediction.[152] In 
addition, in our material we were able to use the mean ACR value of three samples which 
reduces the random variation. On the other hand, variation in urinary albumin excretion over 
weeks was not captured by our method. 
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Myocardial infarction and ischemic stroke 
 In article III, the hard endpoints ischemic stroke and myocardial infarction were outcomes. 
As described, the events were adjudicated according to validated criteria by trained personnel. 
However, some misclassification is likely to occur. Only certain cases of myocardial 
infarction and ischemic strokes were included. In case of missing information, true events 
could erroneously have been classified as uncertain and thus not included as an endpoint. On 
the other hand, borderline cases could erroneously be classified as true events. Moreover, it 




 Important data used in our studies was derived from questionnaires. This may have been a 
source of information bias. In particular, data derived from questions that may have been 
perceived as value-laden may have been biased. Participants may hesitate to fully answer such 
questions because they feel that they are too personal, or they may be uncomfortable with for 
instance their alcohol use or level of activity. Questions may also have been misunderstood 
leading to possible classification bias. Several self-reported lifestyle factors were included as 
covariates in all three articles. In spite of the limitations mentioned above, high validity has 
been found for self-reported questionnaires regarding smoking habits [153] and hard physical 
activity.[154] Both hard and moderate leisure time physical activity were reported in Tromsø 




Dichotomizing of variables 
In our studies, we chose to dichotomize several of the exposure and outcome-variables which 
has a potential to introduce bias. In article I, the participants were dichotomized into BMI 
above or below 25 kg/m². Furthermore, each of component of the MetS is a continuous 
biological variable that has been dichotomized by the use of constructed cut-offs. Also in 
article II, the SUA change variable was categorized into SUA increasers and non-increasers, 
and the endpoint RD was a dichotomous constructed variable. The most obvious problem 
with this categorizing is the interpretation of the observations close to the cut-offs. In the 
statistical analyses these observations are treated as opposites, whereas they indeed are pretty 
close. In an article discussing “why dichotomization of continuous variables is a bad idea”, 
the authors address this issue thoroughly. [156] First of all, dichotomizing is recognized as 
widespread in clinical research, and practical in the sense that one sometimes needs the 
distinctions normal/abnormal, cancerous/benign etc. However, simplicity achieved is gained 
at a cost. Information and power are inevitably lost; dichotomizing is equivalent to losing a 
third of the data. It also increases the possibility for false positive results. [156] These 
problems concerning dichotomizing might have been a problem also in our results. However, 
having a large sample as in our study is an advantage compared to smaller studies because 
statistical power is retained. 
 
5.1.4 Type I and type II error 
When evaluating the results of statistical analysis in medical research, one should always 
consider the possibility of type I and type II errors. A type I error is the error in rejecting a 
null hypothesis when in fact it is true (equal to the false positive error).[136] In making this 
error, one is claiming a difference between comparison groups when there is, in fact, none in 
the source population. Apparent differences have occurred by pure chance. In article I we 
found that 59 µmol/L (1 mg/dL) increase in SUA was associated with increased risk of 
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hypertension (OR, 1.44, p=0.001) in participants with overweight. However, statistics do have 
the limitation that it will always be a matter of probabilities. In the result above, we can say 
that there is a 99.9 probability that this result did not occur by coincidence. Still, there is a 0.1 
percent possibility of a type I error, and that type of error can never be completely eliminated. 
To minimize type I errors, the level of significance (alpha) should be set at a low level 
(usually less than 5 %).  
In this context, however, it should be mentioned that statistical significance and clinical 
relevance are two different matters. Minimal clinical differences may yield statistical 
significance simply due to a large sample size. Thus; the magnitudes of effects and measures 
should be evaluated critically. OR at 1.44, meaning a 44% increased risk (per unit SUA 
increase) of a common condition, such as hypertension, probably is clinically relevant. The 
same applies to the findings in article II and III, where increased SUA was associated with 
RD, stroke in men and all-cause mortality in both genders. 
A type II error is failing to reject a null hypothesis when it is false, i.e. disregard an effect that 
is in fact present.[136] Most studies aim to have less than 10-20 percent (beta) possibility of 
such an error. The power of a study is the possibility that a type II error will not occur, i.e. 1 – 
beta. Most studies aim for a power of 80-90%.[136] Type II error is usually related to a 
sample size that is too small. This limits the possibility to stratify the population into 
subgroups for analyses. We cannot rule out that the lack of significant association between 
SUA increase and stroke in women was due to lack of power, i.e. a type II error. 
 
5.1.5 Interaction 
Sometimes the strength of the association between two variables differs, depending on the 
value of a third variable. This is usually called effect modification by epidemiologists and 
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interaction by biostatisticians. [138] The exposure-outcome association differs in different 
levels (strata) of an effect modifier. [136]  
In article I, we found that the relationship between SUA and hypertension was modified by a 
third variable: BMI. When overweight was present, SUA was associated with hypertension. 
The same was the case for SUA and elevation of glucose. In overweight subjects, but not in 
the absence of overweight, a rise in SUA was associated with a significant increase in 
glucose. However, we did not find interaction between SUA and overweight for the 
association with MetS. This may lead to a hypothesis that there may be some biologically 
important mechanisms in the interplay between SUA, hypertension and overweight. 
When we studied the association between change in SUA and RD in article II, there was no 
significant interaction between gender and SUA change during follow-up for the prediction of 
RD. Therefore, we ran the multivariable analyses in the entire cohort not stratified by gender, 
thereby increasing the statistical power. However, we ran gender specific analyses as well, 
and did not reveal different results; these data are not shown. 
In article III, SUA was associated with all-cause mortality in both genders, and ischemic 
stroke in men. In our study, there was no statistically significant interaction between SUA and 
gender, but still these differences were revealed when performing the analyses stratified by 
gender. There is evidence in the literature that there may be biological differences in the way 
SUA affects vasculature in men and women, [157] and in cardiovascular biology in general 
there are important differences between men and women. A negative test for interaction does 
not exclude the possibility that there may be biological differences of importance. However, 
in article III, we cannot rule out that lack of statistical power preclude the gender differences 




Confounding is bias of the estimated effect of an exposure on an outcome due to the presence 
of a common cause of the exposure and outcome.[141]  Confounding is an important issue in 
observational designs, and may lead to underestimation, overestimation or even change the 
sign of the estimated effect.[142]  
Confounding can be reduced by proper adjustment. Exploring data is not sufficient to identify 
whether a variable is a confounder, and such evaluation of confounding may lead to bias. 
[141, 142, 158] Other evidence, like pathophysiological and clinical knowledge and external 
data, is needed. A confounder cannot be an effect of the disease or the exposure. [140, 142]  
As opposed to effect modification (interaction), the exposure-outcome association of a 
confounder is similar in all levels (strata). 
 
Residual confounding 
The bias that remains after unsuccessful adjustment for confounders is called residual 




In contrast to the confounder, a mediator represents a step in the causal pathway between the 
exposure and the outcome. [141, 142] Such a variable will also be associated with both the 
exposure and the outcome.  
 
Confounding in article I, II and III 
In article I, SUA was associated with hypertension and elevated glucose in the overweight 
group and with MetS in the entire cohort. 
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There is a possibility for unmeasured confounding in these findings. Insulin resistance could 
be a confounding factor, although we adjusted for blood glucose at baseline. There is, 
however, evidence in the literature that a rise in SUA appears before insulin resistance.[159] 
Inflammation is also a possible confounder in these associations. 
Recent literature in obesity pathophysiology focuses on adiponectin, an adipocytokine 
secreted from fat tissue. UA is able to downregulate adiponectin, and this cytokine is 
negatively associated with BMI and body-fat. [160, 161] Low level is associated with 
development of hypertension.  Unfortunately, we did not measure adiponectin in our study in 
1994/95.  
On the other hand, it is possible that insulin resistance, inflammation and adiponectin may 
represent a step in the causal pathway between SUA and the outcomes, and consequently 
these factors may be mediators, which not necessarily should be adjusted for. 
In article II we found that increasing SUA was associated with increased ACR and reduced 
eGFR. In previous literature, multiple risk factor adjustment has been done to a varying 
degree. We were able to adjust for age, baseline SUA, eGFR, ACR, BP, cholesterol, smoking, 
antihypertensive treatment, including diuretics, and life style factors. However, we can never 
rule out that we have possible unmeasured confounders that we should have been aware of. In 
addition, the same issue as in article I may represent a problem; some of the presumed 
confounding factors could in reality be mediators. In particular, elevated BP could represent a 
causal step between SUA rise and RD. However, basal research has shown that renal damage 
in the presence of hyperuricemia also occurs when BP is kept normal.[18]We ran the analyses 
with and without BP in the regression models and still found a significant association between 
SUA rise and RD (data not shown). 
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In article III, we found that SUA was associated with all-cause mortality in both genders and 
ischemic stroke in men. We did not find any significant association between SUA and 
myocardial infarction. In this article, a main point was to thoroughly adjust for multiple 
confounders that earlier studies had not been able to account for. Lack of adjustment for 
important confounders in the literature has been pointed out as a major problem in 
interpreting the association of SUA with cardiovascular endpoints. Some studies have 
included presumed confounders that caused SUA to loose significance; for instance, in the 
Framingham study, the association between SUA and mortality lost its significance when 
diuretics were adjusted for. We included the use of diuretics in our model, and still we found 
that SUA was associated with all-cause mortality. 
We ran a Cox regression model with presumed confounders as independent variables in the 
model. We aimed to find which variables had the greatest impact on the endpoints with a 
theory based, stepwise inclusion of covariates into the regression model. In the literature, RD, 
measured as eGFR and ACR, are regarded as confounders. In our study, these variables were 
adjusted for. For myocardial infarction, SUA lost its significance when lipids were included 
as covariates. However, still residual confounding cannot be ruled out in the main results. 
 
5.1.7 Causality 
In 2005, a systematic review referred to the epidemiologist and statistician Bradford Hill when 
analyzing whether a causal association between SUA and CVD was likely.[126, 162] Bradford 
Hill is usually given credit for the modern RCT. According to Bradford Hill, there is a group 
of minimal conditions necessary to provide adequate evidence of a causal relationship between 
an incidence and a possible consequence: Temporality, strength, consistency, biological 
gradient, plausibility and experimental evidence.[162] However, failure to satisfy them does 
not disprove a causal association.  
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The effect has to occur after the cause, and this is the only absolute criterion. All our articles 
describe prospective studies, with baseline SUA as a predictor of future endpoints. However, 
in article I and II, we also studied longitudinal change in SUA as a major exposure variable. In 
article II it may be problematic that the final SUA measurement and the endpoints were assessed 
simultaneously, as discussed earlier. Strength, consistency and biological plausibility has also 
been discussed in earlier parts of the thesis. Experimental knowledge refers to the use of RCTs, 
which is the superior design in establishing causality. When performed adequately, this method 
is able to exclude confounding. Our works are observational studies, which have its limitations 
as described above. However, an increasing number of RCTs are performed with UA lowering 





5.2 Discussion of main results 
5.2.1 Paper I 
In article I, in contrast to other studies, we stratified the population into overweight and not 
overweight subjects, and made different findings between the groups. In the group with 
normal-weight participants, SUA was not associated with hypertension and elevated fasting 
glucose. However, among the overweight persons, elevation of SUA of 59 µmol/L gave a 44 
% increased risk of hypertension and a 14 % increased risk of elevated fasting glucose. The 
associations between SUA and hypertension have been explored for more than a century. In a 
recent meta-analysis, 59 µmol/L (1 mg/dL) SUA increase was reported to be associated with a 
statistically significant elevation in incident hypertension.[35] It has been claimed that an 
elevated SUA is the independent risk factor for hypertension that is the most reproducible to 
date.[163] Although SUA and hypertension have been extensively studied, few studies have 
studied different strata of weight.  
A multitude of studies, in an effort to explain how hyperuricemia can lead to hypertension, 
have proposed interlinked mechanisms such as endothelial dysfunction and reduction in 
endothelial NO levels,[164, 165] oxidative stress,[166]  and activation of the renin-
angiotensin-aldosterone-system  [167] and renal microvascular lesions. [18]  
Under certain circumstances, increased activity of XO, detected as increased production of 
UA, will lead to increased oxidative stress, which, in turn, can be detrimental in the state of 
reduced antioxidant capacity that accumulated fat creates. Persons with overweight may 
possibly be more exposed to this mechanism.[168]  
Furthermore, UA can affect adipocytes by inducing upregulation of pro-inflammatory factors 
and downregulation of the insulin sensitizer and anti-inflammatory factor adiponectin.[161] 
Unfortunately, we have not measured adiponectin, but it has been shown that adiponectin is 
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negatively associated with BMI and body-fat.[160] Since low level of adiponectin is 
associated with the development of hypertension [169] and insulin resistance, [170] it could 
be speculated that adiponectin is part of the link between UA and hypertension and insulin 
resistance, and also be a part of an explanation why UA is associated with new onset 
hypertension and elevated glucose in the overweight but not the normal-weight subjects in our 
study.  
Furthermore, a study found increased angiotensinogen levels in persons with hypertension 
and overweight (BMI ≥ 25 kg/m²), compared to persons with hypertension and normal-weight 
(BMI < 25 kg/m²), in the presence of hyperuricemia. [171] This could also be a mechanism by 
which UA is associated with obesity-related hypertension and impaired fasting glucose.  
In article I we also found that baseline and increasing SUA was associated with development 
of MetS. An elevation of 59 µmol/L SUA gave a 32 % increased risk of MetS among both 
lean and overweight subjects. Earlier studies have also reported an association between SUA 
and MetS. [64, 172, 173] A Japanese prospective study came up with a negative result, but 
they had a shorter duration, and did not adjust for baseline SUA, which we did in our study. 
Our study also has other important strengths: the large size, solid attendance rate, long follow-
up time, use of SUA as a continuous variable, and the ability to correct for confounders such 
as eGFR, use of diuretics and all the traditional cardiovascular risk factors. However, as 
described above, a major shortcoming of our study was the lack of fasting blood samples. In 
addition, only one single measurement of SUA was done in each survey. The fact that our 
study population comprised largely of healthy, middle-aged to elderly Caucasians, can be 
viewed as both a weakness and a strength; the results may not be generalizable to dissimilar 
populations, but the homogeneity of our cohort may have prevented dilution of our findings 
due to important diversities in baseline properties. 
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5.2.2 Paper II 
Being in the highest tertile of SUA change, corresponding to an increase in SUA of more than 
33 μmol/L over 13 years, was an independent risk factor for RD defined as increased ACR 
and/or a reduced eGFR. This result for eGFR was consistent whether the population had a 
long time follow-up of 13 years or whether the follow-up time was shorter, and the results 
were similar when participants with baseline RD were excluded. Although the OR for 
moderately reduced eGFR was higher than the OR for ACR ≥1.13 mg/mmol, longitudinally 
increasing SUA was significantly associated also with the development of albuminuria after 
13 years. The associations between baseline SUA and the renal endpoints were not significant 
when the longitudinal change in SUA was not adjusted for. The reason for this is unclear, but 
it is possible that the association between baseline SUA and the renal endpoints within the 
SUA increaser-and non-increaser groups, respectively, becomes obscured when the whole 
cohort is studied without this group division. In our study, SUA increase was associated with 
worsening eGFR and ACR over time, and these two markers independently predict advanced 
stage CKD, CVD and mortality. [174-182] Therefore, our findings may have clinical 
importance. 
Our study is in concordance with the results from a meta-analysis that included fifteen 
cohorts, as described earlier in this thesis. [14] One difference, however, was the age 
distribution. In our study, we found an effect in participants with a mean age of 56, whereas in 
the meta-analysis, the positive association between SUA and CKD was more pronounced 
among groups with a mean age < 60 years, and no association was observed in cohorts with a 
mean age ≥60 years. Thus, it is possible that our results would have been stronger if mainly 
younger persons were investigated. 
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Most studies use eGFR <60 mL/min/1.73 m2 as the only endpoint when considering CKD. 
We also included ACR ≥ 1.13 mg/mmol as an outcome, and showed that increasing SUA 
independently predicted low grade albuminuria. A major methodological problem concerning 
UA and kidney function is that of reverse causality as explained on page 23 in this thesis. In 
order to reduce bias concerning revers causality, all patients with decreased eGFR were 
excluded at baseline of the analysis. We also have aimed to reduce this problem by adjusting 
for baseline eGFR. 
Also, the fact that we found an association between SUA and development of increased 
albuminuria in addition to decreased eGFR, strengthens the assumption that UA may exert a 
harmful effect on the kidney. 
A weakness of several previous epidemiological studies, as also stated by other authors, is the 
lack of information on diuretics. We have obtained that information in our material of almost 
3000 subjects, and found that there were significantly more users of diuretics in SUA 
increasers. In men, 19 % of the SUA increasers used diuretics compared to 6 % of SUA non-
increasers. (13 vs 6 % in women) However, when adjusting for the use of diuretics in the 
analyses, SUA still had a significant association with RD. 
Few previous studies had information on the use of allopurinol. In our study, information 
about current use of allopurinol at baseline was available. However, there were few 
allopurinol-users (less than 0.2 % at baseline) included in the study. Moreover, the use of 
allopurinol was not a significant predictor in the univariate analyses and therefore not 
included in the multivariable models. 
Other strengths of our study were the prospective design, a large cohort from the general 
population with a high attendance rate, and a long observation time (13 years). We also had 
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ACR measurements from three unfrozen urine specimens, reducing the effect of day-to-day 
variation.[183]  
As described earlier, only persons with three SUA measurements (Tromsø 4, 5 and 6) were 
included in the cohort. Analyses showed that the excluded persons were less healthy at 
baseline, and this may have influenced the results of the study. However, it is reasonable to 
believe that the inclusion of these less healthy individuals would have strengthened rather 
than weakened the reported associations.  
To summarize, this study confirms the growing evidence suggesting that SUA is a risk factor 
also for renal damage. Moreover, longitudinally increasing SUA may be a risk factor per se. 
 
5.2.3 Paper III 
In this prospective study of 5700 participants from the general population,  one SD (87 
μmol/L) increase in SUA was significantly associated with a 31% increased risk for ischemic 
stroke in men, and all-cause mortality risk was increased in both genders; 11 % in men, and 
16 % in women, after multivariable adjustments. There was no association between SUA and 
myocardial infarction after adjustment for lipids. Interaction between SUA and gender in the 
association with stroke was not observed in our study.  
The association between SUA and ischemic stroke has been found in previous studies. [114, 
184, 185] However, the Framingham study failed to show an independent association of SUA 
with stroke.[186] A systematic review and meta-analysis from 2009 of 16 prospective cohort 
studies, found that the elevated SUA level is associated with a modest but statistically 
significant increased risk of stroke incidence and mortality.[185] In our study, we did not find 
an association in women; SUA lost its significance when BP and BMI were adjusted for. This 
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result is in contrast to the large Swedish AMORIS [114] study, which found UA to be more 
strongly related to stroke in women than in men. In the AMORIS study, more than 400000 
participants were followed, and more than 11000 strokes were registered, and thus this study 
is unique due to its size. A limitation of the AMORIS study, was the lack of information 
about the use of antihypertensive drugs. In our study, 430 ischemic strokes occurred, and thus 
we might have lacked the power to show significant associations in women. When we look at 
the figure of the incidence rates in our study (Figure 3 in article 3), the incidence of events are 
increasing with increasing tertiles of SUA in both genders, but there were fewer events among 
women. Statistical analysis did not yield significant associations, which could be due to too 
few events among women. 
Another explanation for the gender differences in our study might be actual biological 
differences in these associations. Differences in risk estimates for stroke between genders may 
relate to gender-specific differences in vascular biology. Vlachopoulos et al. [157] reported 
that in newly diagnosed hypertensive persons, UA was associated with increased aortic 
stiffness in both genders, but a negative association with arterial wave reflection was observed 
only in women. Such differences in vascular function could influence the tendency to develop 
stroke. In an article from 2016, however, the risk of stoke with increments in SUA in women 
increased by 15% for each 59 µmol/L  increase in plasma UA (95% CI 3%-28%), but was no 
longer significant after adjustment for cardiovascular risk factors, particularly history of 
hypertension. [187]  
It has been suggested that UA may have harmful effects on platelet function, [188] and cause 
endothelial dysfunction. In one study it was shown that UA could induce expression of CRP 
in human vascular endothelial and smooth muscle cells, inhibit endothelial cell proliferation 
and migration and impair NO production. [189] Vannorsdall et al. reported that even a mild 
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elevation of SUA was associated with cerebral ischemia. One hundred eighty study 
participants aged 20 to 96 years completed neuropsychological testing, laboratory blood 
studies, and a brain MRI scan. [190] It was suggested that impaired vascular tone and 
endothelial dysfunction could contribute to ischemic changes, because they permit 
cerebrospinal fluid to cross the blood-brain barrier and cause areas of edema.[190] 
In the AMORIS study, the authors referred to the urate redox shuttle theory [191]: UA may 
turn into a pro-oxidant risk factor once the environment becomes atherosclerotic with plaque 
formation within the arterial wall, or it may become elevated as a response to an up-regulated 
XO activity with deleterious peroxidation and other processes affecting plaque formation and 
stability.[192, 193]    
Quite opposite to this, it has been shown that treatment with UA in combination with 
thrombolysis was of benefit to patients suffering from acute stroke, as described earlier. [127] 
UA is one of the most important endogenous antioxidants in the human brain, and high 
circulating UA concentration could play a role against the deleterious effect of free radicals 
produced upstream in the synthesis of UA.[194]  
We observed a significant association of SUA with all-cause mortality, with a modest 
increase in mortality risk in both genders. In the Framingham study, [186] no association was 
observed with all-cause mortality after adjustments for age, BP, smoking, BMI, total 
cholesterol, intake of alcohol and medication. On the other hand, the NHANES I study [16] 
reported a 13% increased mortality risk in women in fully adjusted analyses, but only with 
non-significant associations in men. The fact that the SUA level in women tends to increase 
during the fifth to the seventh decade due to postmenopausal reduction in UA excretion [195, 
196] and being flat or slightly declining in men, [186] may influence the gender specific 
association with endpoints.  
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No independent association between increment in SUA and myocardial infarction was 
observed in the present study. Total- and HDL-cholesterol abolished the effect of SUA on 
future myocardial infarction.  
The Framingham Study[186] is one of the largest studies on the association of SUA with 
CVD in the general population. Our study differs from the Framingham Study in many ways, 
and as mentioned earlier, the mean age in the Tromsø study was relatively high. Mean age 
was 47 years in the Framingham cohort compared with 60 years in the Tromsø cohort, and 
thus mortality rate was lower in the Framingham study (12.4 per 1000 person years compared 
to 18.9 per 1000 person years). The observation time in our study was longer than in most 
previous studies, and this may explain why we were able to detect associations in a study 
population where high-risk subjects had been excluded.  
A recent study published in 2016 examined the controversy regarding the association between 
hyperuricemia and CHD. [197] This was a systematic review and dose-response meta-
analysis of 29 prospective cohort studies (n = 958410 participants, including our study on 
SUA and cardiovascular endpoints and mortality). In contrast to our results with no 
association between SUA and myocardial infarction, hyperuricemia in the meta-analysis was 
associated with increased risk of CHD morbidity (adjusted RR 1.13; 95% CI 1.05-1.21). As in 
our study, increased mortality risk was found, however the meta-analysis specified CHD 
mortality while we explored all-cause mortality. For each increase of 1 mg/dl in UA level, the 
pooled multivariate RR of CHD mortality was 1.13 (95% CI 1.06 -1.20). The authors also 
found that hyperuricemia may increase the risk of CHD events, particularly CHD mortality in 
females[197] which we did not find in our study. 
Taken together, the meta-analysis showed some differences and some similarities compared 
to our study, but the studies included had some heterogeneity, and as studies from all over the 
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world was included, ethnical and environmental differences also could have been of 
significance.  
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6. CONCLUSIONS AND PERSPECTIVES 
In accordance with previous studies, our research supports the suggested interplay between 
UA, obesity, MetS and hypertension. Further studies should examine the exact causal 
relationship. With regards to renal damage, not only SUA per se, but also increase in SUA 
seems to be of importance. We conclude that SUA is an independent risk marker of all-cause 
mortality in both genders, ischemic stroke in men and that gender-specific analyses should be 
given priority in future studies. 
Other approaches could also be of importance in assessing the impact of UA: 
 
•Our studies have gained information on renal function with repeated measurements over 
many years. Still, we use eGFR, and not exact GFR measurements. However, exact 
information on renal function has been gained by the RENIS-T6 group, and in the RENIS 
Follow-up Study. In the future, we hope to study the association between SUA and age-
related change in measured GFR in a collaboration project with the RENIS researchers. 
 
•As described initially, SUA is generated from xanthine and hypoxanthine up-stream, and 
excreted in the urine and feces. By studying the serum concentrations and urinary excretion of 
metabolites and precursors more thoroughly, causes of hyperuricemia among individuals 
could be differentiated. In theory, this could lead to a more targeted strategy for SUA 
reduction in each individual. 
 
•SUA reduction in RCTs in adolescents was briefly described above. Hyperuricemia among 
the youngest is usually combined with overweight and is an area of utterly importance. Early 
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intervention may prevent this group from developing serious health problems later in life. In 
Fit Futures, a special survey of adolescents run by the Tromsø study, many participants were 
overweight. Blood samples have been collected, and assessment of SUA, and possibly a 
targeted follow-up for the participants at risk, may be highly valuable. 
 
•Adiponectin is among the new markers that may be of importance in obesity, inflammation 
and SUA. In the future, it would be interesting to explore associations more thoroughly. 
Currently Tromsø 7 is running, which hopefully will yield new opportunities in such 
assessment. 
 
• Some of our data was based upon biological samples and questionnaires collected 21–22 
years ago, with endpoint registration only 7 years later (Met S and hypertension in article I). 
Both lifestyles and pharmacological treatments have changed during these years, and it would 
be of interest and importance to confirm these finding in future studies. 
 
•As the knowledge in this field has expanded, RCTs on lowering SUA in subgroups at high 
risk should be performed, which may give firm answers to the role of SUA in cardiovascular 
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Medisin mot høyt blodtrykk ..........................
Kolesterolsenkende medisin ........................
Leser, ser på fjernsyn eller annen
stillesittende beskjeftigelse?.................................................
Spaserer, sykler eller beveger deg på 
annen måte minst 4 timer i uka?..........................................
(Her skal du også regne med gang eller 
sykling til arbeidsstedet, søndagsturer m.m.)
Driver mosjonsidrett, tyngre hagearbeid e.l.? ......................
(Merk at aktiviteten skal vare minst 4 timer i uka)
Trener hardt eller driver konkurranseidrett 
regelmessig og flere ganger i uka?......................................
Ingen Under 1 1-2 3 og mer
10.1 Hvordan har din fysiske aktivitet i fritiden vært 
det siste året?
Tenk deg et ukentlig gjennomsnitt for året.
Arbeidsvei regnes som fritid. Besvar begge spørsmålene.
11.3 Hvor stor interesse viser folk for det du gjør?
(Sett bare ett kryss)
11.4 Hvor mange foreninger, lag, grupper,
kirkesamfunn e.l. deltar du i på fritiden?         Antall
(Skriv 0 hvis ingen)
11.5 Føler du at du kan påvirke det som skjer i 
lokalsamfunnet der du bor? (Sett bare ett kryss)
12.1 Har en eller flere av dine foreldre eller søsken 
hatt hjerteinfarkt (sår på hjertet) eller
angina pectoris (hjertekrampe)? ........................
12.2 Kryss av for de slektningene som har eller har
hatt noen av sykdommene: (Sett kryss for hver linje)
Hjerneslag eller
hjerneblødning.............





12.3 Hvis noen slektninger har diabetes, i hvilken alder fikk de
diabetes (hvis for eks. flere søsken, før opp den som fikk det 
tidligst i livet):
11.2 Hvor mange gode venner har du? Antall venner
Regn med de du kan snakke fortrolig med
og som kan gi deg hjelp dersom du trenger det.
Tell ikke med de du bor sammen med, men 
ta med andre slektninger.
10.2 Angi bevegelse og kroppslig anstrengelse i din fritid. Hvis 
aktiviteten varierer meget f.eks. mellom sommer og vinter, så
ta et gjennomsnitt. Spørsmålet gjelder bare det siste året.
(Sett kryss i den ruta som passer best)
1 2 3 4
10. MOSJON OG FYSISK AKTIVITET
11. FAMILIE OG VENNER
12. SYKDOM I FAMILIEN
13. BRUK AV MEDISINER
14. RESTEN AV SKJEMAET SKAL BARE
BESVARES AV KVINNER
13.1 Bruker du?
14.1 Hvor gammel var du da du fikk 
menstruasjon aller første gang? Alder i år
14.2 Hvis du ikke lenger får menstruasjon,
hvor gammel var du da den sluttet? Alder i år
14.3 Er du gravid nå?
14.4 Hvor mange barn har du født? Antall barn
14.5 Bruker du, eller har du brukt?
(Sett ett kryss for hver linje)
13.2 Hvor ofte har du i løpet av de siste 4 ukene brukt 
følgende medisiner?
(Sett ett kryss pr. linje)
13.3 For de medisinene som du har krysset av for i pkt. 13.1 og 13.2,























Mors alder Fars alder Brors alder Søsters alder Barns alder
Far Bror Søster Barn
Ingen
av disse
Ja, en del Ja, i liten grad Nei
Har ikke
forsøkt




Med medisiner mener vi her medisiner kjøpt på apotek.





Medisin mot depresjon .............
Annen medisin på resept..........
P-pille/minipille/p-sprøyte............
Hormonspiral (ikke vanlig spiral)
Østrogen (tabletter eller plaster)
Østrogen (krem eller stikkpiller)
Angi navnet og hvilken grunn det er til at du tar/har tatt
disse (sykdom eller symptom):











Navn på medisinen: Grunn til bruk Inntil Ett år
(ett navn pr. linje): av medisinen: 1 år eller mer
Dersom det ikke er nok plass her, kan du fortsette på eget ark som du legger ved.


































Før, men ikke nå Aldri
14.6 Hvis du bruker/har brukt reseptpliktig østrogen:
Hvor lenge har du brukt dette? Antall år
14.7 Hvis du bruker p-pille, minipille, p-sprøyte,
hormonspiral eller østrogen; hvilket merke bruker du?
Personlig innbydelse
Ikke skriv her:
1 2 3 4
Helse- 
undersøkelsen
5.3 (Kommune) (Fylke) (Land)
9.3 (Virksomhet) 9.4 (Yrke) 14.7 (Merke)
1 2 3 4 5
11.1 Bor du sammen med:
Ektefelle/samboer? ......................................
NEIJA











2.1 Har du vært plaget med smerter og/eller stivhet 
i muskler og ledd i løpet av de siste 4 ukene?
(Varighet angis bare hvis du har hatt plager)
5.1 Hvor lenge har du samlet bodd i fylket?
(Sett 0 hvis mindre enn et halvt år)
5.2 Hvor lenge har du samlet bodd i kommunen?
(Sett 0 hvis mindre enn et halvt år)
5.3 Hvor bodde du det meste av tiden før du fylte 16 år?




Annet fylke i Norge .... Hvilket:
Utenfor Norge ............ Land:
5.4 Har du flyttet i løpet av de siste fem årene?
Nei Ja, en gang Ja, flere ganger
1 2 3
NEIJA
1.1 Hvordan er helsen din nå? (Sett bare ett kryss)
Dårlig Ikke helt god God Svært god
1 2 3 4
1.4 Får du smerter eller ubehag i brystet når du:
Går i bakker, trapper eller fort på flat mark?.................
1.6 Dersom du stopper, forsvinner smertene da
etter mindre enn 10 minutter? ...................................
1.7 Kan slike smerter opptre selv om du er i ro? ..........
1.5 Hvis du får slike smerter, pleier du da å:










Øvre del av ryggen ...
Korsryggen................
Hofter, ben, føtter ......
Andre steder..............











2.2 Har du noen gang hatt:
Brudd i håndledd/underarm? .....................
Lårhalsbrudd? ............................................
1. EGEN HELSE 3. ANDRE PLAGER 7. MAT OG DRIKKE 8. RØYKING
9. UTDANNING OG ARBEID
4. BRUK AV HELSETJENESTER
5. OPPVEKST OG TILHØRIGHET
6. VEKT
2. MUSKEL OG SKJELETTPLAGER
3.1 Under finner du en liste over ulike problemer. Har du opplevd 
noe av dette den siste uken (til og med i dag)?
(Sett ett kryss for hver plage)
Plutselig frykt uten grunn..........................
Føler deg redd eller engstelig...................
Matthet eller svimmelhet ..........................
Føler deg anspent eller oppjaget..............
Lett for å klandre deg selv........................
Søvnproblemer .........................................
Nedtrykt, tungsindig..................................
Følelse av å være unyttig, lite verd ..........
Følelse av at alt er et slit ..........................









1 2 3 4
7.1 Hvor ofte spiser du vanligvis disse matvarene?
(Sett ett kryss pr. linje)
7.2 Hva slags fett bruker du oftest? (Sett ett kryss pr. linje)
7.3 Bruker du følgende kosttilskudd:
8.1 Hvor lenge er du vanligvis daglig 
tilstede i røykfylt rom? Antall hele timer
8.2 Røykte noen av de voksne hjemme 
da du vokste opp?.................................................
8.3 Bor du, eller har du bodd, sammen med 
noen dagligrøykere etter at du fylte 20 år? ........
8.4 Har du røykt/røyker du daglig? ...............
Hvis ALDRI: Hopp til spørsmål 9 (UTDANNING OG ARBEID)
8.5 Hvis du røyker daglig nå, røyker du:
8.6 Hvis du har røykt daglig tidligere, hvor 
lenge er det siden du sluttet? Antall år
8.7 Hvis du røyker daglig nå eller har røykt 
tidligere:
4.1 Hvor mange ganger de siste 12 månedene har du selv brukt:
(Sett ett kryss for hver linje)
Allmennpraktiserende lege .......................
Bedriftslege...............................................
Psykolog eller psykiater ............................
(privat eller på poliklinikk)
Annen spesialist (privat eller på poliklinikk)
























Vitamin- og/eller mineraltilskudd? ..........
7.4 Hvor mye drikker du vanligvis av følgende?
(Sett ett kryss pr. linje)
7.5 Drikker du vanligvis brus/cola: Med sukker       1 Uten sukker      2
7.6 Hvor mange kopper kaffe og te drikker du daglig?
(Sett 0 for de typene du ikke drikker daglig)
7.7 Omtrent hvor ofte har du i løpet av det siste året drukket alkohol?
(Lettøl og alkoholfritt øl regnes ikke med)
7.8 Når du har drukket alkohol, hvor mange glass 
eller drinker har du vanligvis drukket?           Antall
7.9 Omtrent hvor mange ganger i løpet av det siste 
året har du drukket så mye som minst 5 glass 











3 g. el. mer
pr.dag









Ja, daglig Iblant Nei
1 2 3 4 5 6
Helmelk, kefir, yoghurt ............











































1 2 3 4
5 6 7 8
7.10 Når du drikker, drikker du da vanligvis: (Sett ett eller flere kryss)
Øl Vin Brennevin
9.1 Hvor mange års skolegang
har du gjennomført? Antall år
(Ta med alle år du har gått på skole eller studert)
9.2 Er du i inntektsgivende arbeid?
9.3 Beskriv virksomheten på det arbeidsstedet (avdelingen) 
der du utførte inntektsgivende arbeid i lengst tid de 
siste 12 mnd. (F.eks. regnskapsbyrå, ungdomsskole, 
barneavd. på sykehus, snekkerverksted, bilverksted, bank, 
dagligvarehandel e.l.)
Virksomhet:
Hvis pensjonert, skriv tidligere hovedvirksomhet og yrke.
Gjelder også 9.4
9.4 Hvilket yrke/tittel har eller hadde du på dette arbeidsstedet? 
(F.eks. sekretær, lærer, industriarbeider, barnepleier, 
møbelsnekker, avdelingsleder, selger, sjåfør e.l.)
Yrke:
9.5 Arbeider du i ditt hovedyrke som selvstendig, som ansatt 
eller som familiemedlem uten fast avtalt lønn?
9.6 Mener du at du står i fare for å miste ditt 
nåværende arbeid eller inntekt de nærmeste 
2 årene?..................................................................







Sykepenger (er sykmeldt) ........................................
Alderstrygd, førtidspensjon (AFP) eller
etterlattepensjon.......................................................
Rehabiliterings-/attføringspenger .............................
Uførepensjon (hel eller delvis)..................................
Dagpenger under arbeidsledighet............................
Sosialhjelp/-stønad ...................................................
Overgangsstønad for enslige forsørgere ..................
Hvor mange sigaretter røyker eller røykte 
du vanligvis daglig? Antall sigaretter
Hvor gammel var du da du begynte å 
røyke daglig? Alder i år




Ja, full tid Ja, deltid Nei1 2 3
Selvstendig Ansatt Familiemedlem
1.3 Har du merket anfall med plutselig endring i 











Navn på medisinen: Grunn til bruk Inntil Ett år
(ett navn pr. linje): av medisinen: 1 år eller mer
Medisin mot høyt blodtrykk ...................
Kolesterolsenkende medisin .................
Medisin mot osteoporose (benskjørhet)
Insulin ...................................................
Tabletter mot sukkersyke ......................
Hvor stor interesse viser folk for det du gjør?
(Sett bare ett kryss)
Hvor mange foreninger, lag, grupper,
kirkesamfunn e.l. deltar du i ? Antall
(Skriv 0 hvis ingen)
Bor du: Hjemme? Institusjon/bofellesskap?
Bor du sammen med:
Ektefelle/samboer? .......................
Andre personer? ...........................
Hvor mange gode venner har du?
Regn med de du kan snakke fortrolig med
og som kan gi deg hjelp når du trenger det.
Tell ikke med de du bor sammen med, men ta
med barn og andre slektninger. ...........................
Hvor mange ganger de siste 12 månedene
har du selv brukt:
(Sett ett kryss for hver linje)
Er du trygg på at du kan få
hjelp av helseog hjemme-
tjenesten hvis du trenger det?
E11. BRUK AV HELSETJENESTER
E12. FAMILIE OG VENNER
E13. OPPVEKST OG TILHØRIGHET
E14. BRUK AV MEDISINER
E15. RESTEN AV SKJEMAET SKAL BARE
BESVARES AV KVINNER
Bruker du?
(Sett ett kryss for hver linje)
Hvor gammel var du da du fikk 
menstruasjon aller første gang? Alder i år
Hvor gammel var du da
menstruasjonen sluttet? Alder i år
Hvor mange barn har du født? Antall barn
Bruker du, eller har du brukt østrogenmedisin?
Hvor ofte har du i løpet av de siste 4 ukene brukt 
følgende medisiner?














1 2 3 4 5
Med medisiner mener vi her medisiner kjøpt på apotek.
Kosttilskudd og vitaminer regnes ikke med her.
Smertestillende uten resept .......




Annen medisin på resept ...........
Tabletter eller plaster ...................
Krem eller stikkpiller .....................
Angi navnet på de medisinene du bruker nå, og hva grunnen
er til at du tar medisinene (sykdom eller symptom):










Dersom det ikke er nok plass her, kan du fortsette på eget ark som du legger ved.
Hvor lenge har du
brukt medisinen?
Aldri Før Nå
Hvis du bruker østrogen; hvilket merke bruker du nå?
Har du noen gang brukt P-pille? ..........................
E
Ikke skriv her:
E13 (Kommune) (Fylke) (Land) E15 (Merke)
1 2 3 4
Allmennpraktiserende lege................
Spesialist (privat eller på poliklinikk)












Hvor lenge har du samlet bodd i fylket?
Hvor lenge har du samlet bodd i kommunen?
Hvor bodde du det meste av tiden før du fylte 16 år?
(Kryss av for ett alternativ og spesifiser)
Samme kommune .........
Annen kommune
i fylket ............................ Hvilken:
Annet fylke i Norge........ Hvilket:
Utenfor Norge................ Land:
Har du flyttet i løpet av de siste fem årene?


















































Feit fisk (f.eks. laks, 
ørret, makrell, sild)










Har en eller flere av dine foreldre eller søsken hatt:
NEIJA
Hvordan er helsen din nå? (Sett bare ett kryss)
Dårlig Ikke helt god God Svært god
1 2 3 4
Får du smerter eller ubehag i brystet når du:
Går i bakker, trapper eller fort på flat mark? .............
Dersom du stopper, forsvinner smertene da
etter mindre enn 10 minutter?................................
Kan slike smerter opptre selv om du er i ro?.......
Hvis du får slike smerter, pleier du da å:







Hjerteinfarkt (sår på hjertet) eller




E1. EGEN HELSE E3. PLAGER E7. UTDANNING
E8. MAT OG DRIKKE
E9. RØYKING
E10. FUNKSJON OG TRYGGHET
E4. TENNER, MUSKEL OG SKJELETT
E5. MOSJON OG FYSISK AKTIVITET
E6. VEKT
E2. SYKDOM I FAMILIEN
Under finner du en liste over ulike problemer.
Har du opplevd noe av dette den siste uken
(til og med i dag)?
(Sett ett kryss for hver linje)
Plutselig frykt uten grunn ................
Føler deg redd eller engstelig .........
Matthet eller svimmelhet .................
Føler deg anspent eller oppjaget ....
Lett for å klandre deg selv ..............
Søvnproblemer................................
Nedtrykt, tungsindig ........................
Følelse av å være unyttig, lite verd
Følelse av at alt er et slit.................









1 2 3 4
Hvor ofte spiser du vanligvis disse matvarene?
(Sett ett kryss for hver linje)
Bruker du kosttilskudd:
Hvor lenge er du vanligvis daglig 
tilstede i et røykfylt rom? Antall hele timer
Røykte noen av de voksne hjemme 
da du vokste opp?...............................................
Bor du, eller har du bodd, sammen med 
noen dagligrøykere etter at du fylte 20 år? ......
Har du røykt/røyker du daglig?...............
Hvis du ALDRI har røykt daglig;
Hopp til spørsmål E11 (FUNKSJON OG TRYGGHET)
Hvis du røyker daglig nå, røyker du:
Hvis du har røykt daglig tidligere, hvor 
lenge er det siden du sluttet? Antall år
Hvis du røyker daglig nå eller har røykt 
tidligere:
Hvor mange tenner har du mistet/trukket? Antall tenner
(Se bort fra melketenner og visdomstenner)
Anslå din vekt da du var 25 år gammel: hele kg
Tran, trankapsler, fiskeoljekapsler .....
Vitamin- og/eller mineraltilskudd .......
Hvor mye drikker du vanligvis av følgende?













1 2 3 4 5 6
Ja, daglig Iblant Nei
Helmelk, kefir, yoghurt.........
Lettmelk, cultura, lettyoghurt


















1 2 3 4 5
1 2 3
1 2 3 4
Hvor mange års skolegang har du 
gjennomført? Antall år
(Ta med alle år du har gått på skole eller studert)
Ville du følt deg trygg ved å ferdes alene
på kveldstid i nærområdet der du bor?
Når det gjelder førlighet, syn og hørsel, kan du:
(Sett ett kryss for hver linje)
Har du på grunn av varige helseproblemer vansker
med å: (Sett ett kryss for hver linje)
Gå en 5 minutters tur i 
noenlunde raskt tempo? ........
Lese vanlig tekst i aviser,
evt. med briller? .....................
Høre hva som blir sagt
i en normal samtale? .............
Bevege deg rundt i egen bolig? ..............
Komme deg ut av boligen på egen hånd?
Delta i foreningsliv eller andre 
fritidsaktiviteter? ......................................
Bruke offentlige transportmidler? ............








Hvor mange sigaretter røyker eller røykte 
du vanligvis daglig? Antall sigaretter
Hvor gammel var du da du begynte å 
røyke daglig? Alder i år
Hvor mange år til sammen har du 
røykt daglig? Antall år
Ja Litt utrygg Svært utrygg
Har du vært plaget med smerter og/eller stivhet 
i muskler og ledd i løpet av de siste 4 ukene?
Nakke/skuldre.........................
Armer, hender ........................
Øvre del av ryggen.................
Korsryggen.............................








Har du noen gang hatt:
Brudd i håndledd/underarm?.....................
Lårhalsbrudd?............................................
Har du falt i løpet av det siste året? (Sett bare ett kryss)
NEIJA







Under 1Ingen 1-2 3 og mer
Hvordan har din fysiske aktivitet vært det siste året?
Tenk deg et ukentlig gjennomsnitt for året.
Besvar begge spørsmålene.
1 2 3 4














1 2 3Kryss av for de slektningene som har eller har
hatt noen av sykdommene: (Sett kryss for hver linje)
Hjerneslag eller
hjerneblødning..............





Hvis noen slektninger har diabetes, i hvilken alder fikk de
diabetes (hvis for eks. flere søsken, før opp den som fikk




Mors alder Fars alder Brors alder
Søsters
alder Barns alder
Far Bror Søster Barn
Ingen
av disse Omtrent hvor ofte har du i løpet av det siste året drukket
alkohol? (Lettøl og alkoholfritt øl regnes ikke med)
Når du har drukket alkohol, hvor mange glass 
eller drinker har du vanligvis drukket? Antall
Omtrent hvor mange ganger i løpet av det siste 
året har du drukket så mye som minst 5 glass 






















1 2 3 4
5 6 7 8
Antall kopper
Hvor mange kopper kaffe og te drikker du daglig?
(Sett 0 for de typene du ikke drikker daglig)




c Verken god eller dårlig
c Dårlig 
c Meget dårlig
2 Hvordan synes du at helsen din er sammenlignet 






3 Har du eller har du hatt? Ja Nei
Alder første 
gang
Hjerteinfarkt ............................................................... c c
Angina pectoris (hjertekrampe) ....................... c c
Hjerneslag/hjerneblødning ........................... c c
Hjerteflimmer (atrieflimmer) .............................. c c
Høyt blodtrykk ......................................................... c c
Beinskjørhet (osteoporose) .................................. c c
Astma ............................................................................... c c
Kronisk bronkitt/emfysem/KOLS ........... c c
Diabetes ......................................................................... c c
Psykiske plager (som du har søkt hjelp for) ....... c c
Lavt stoffskifte .......................................................... c c
Nyresykdom, unntatt urinveisinfeksjon... c c
Migrene .......................................................................... c c
4 Har du langvarige eller stadig tilbakevendende 
smerter som har vart i 3 måneder eller mer?
c Ja c Nei
5 Hvor ofte har du vært plaget av søvnløshet de siste 
12 måneder? 
c Aldri, eller noen få ganger
c 1-3 ganger i måneden
c Omtrent 1 gang i uken
c Mer enn 1 gang i uken
6 Under finner du en liste over ulike problemer.  
Har du opplevd noe av dette den siste uken  









Plutselig frykt uten grunn ....... c c c c
Føler deg redd eller  
engstelig ................................................ c c c c
Matthet eller svimmelhet ...... c c c c
Føler deg anspent eller 
oppjaget ................................................ c c c c
Lett for å klandre deg selv .... c c c c
Søvnproblemer ................................ c c c c
Nedtrykt, tungsindig .................. c c c c
Følelse av å være unyttig, 
lite verd .................................................. c c c c
Følelse av at alt er et slit ......... c c c c
Følelse av håpløshet  
mht. framtida ................................... c c c c
7 Har du i løpet av de siste 12 måneder vært hos:  
Hvis JA; Hvor mange ganger?
Ja Nei Ant ggr
Fastlege/allmennlege ......................................... c c
Psykiater/psykolog ............................................... c c
Legespesialist utenfor sykehus 
(utenom fastlege/allmennlege/psykiater) ........... c c
Fysioterapeut ............................................................. c c
Kiropraktor ................................................................... c c
Annen behandler
(homøopat, akupunktør, fotsoneterapeut, natur-
medisiner, håndspålegger, healer, synsk el.l) ..... c c
Tannlege/tannpleier ............................................ c c
Skjemaet skal leses optisk. Vennligst bruk blå eller sort 
penn. Du kan ikke bruke komma, bruk blokkbokstaver.
2007 – 2008 Konfidensielt
9 Har du gjennomgått noen form for operasjon i løpet 
av de siste 3 årene?
c Ja c Nei
8 Har du i løpet av de siste 12 måneder vært på sykehus? 
Ja Nei Ant ggr
Innlagt på sykehus ................................................ c c
Konsultasjon ved sykehus uten innleggelse;
Ved psykiatrisk poliklinikk .................. c c
Ved annen sykehuspoliklinikk ........ c c
BRUK AV HELSETJENESTER
HELSE OG SYKDOMMER
19 Hva er din hovedaktivitet? (Sett ett kryss)
c Yrkesaktiv heltid c Hjemmeværende
c Yrkesaktiv deltid c Pensjonist/trygdet
c Arbeidsledig c Student/militærtjeneste
10 Bruker du, eller har du brukt, noen av følgende 






Medisin mot høyt blodtrykk ... c c c
Kolesterolsenkende medisin .... c c c
Medisin mot hjertesykdom .... c c c
Vanndrivende medisin ................ c c c
Medisin mot beinskjørhet 
(osteoporose) ............................................ c c c
Insulin ........................................................ c c c
Diabetesmedisin (tabletter) ........ c c c
Stoffskiftemedisinene  
Thyroxin/levaxin ............................. c c c
11 Hvor ofte har du i løpet av de siste 4 ukene brukt 











på resept ............... c c c c
Smertestillende 
reseptfrie ............... c c c c
Sovemidler .......... c c c c
Beroligende  
medisiner .............. c c c c
Medisin mot 
depresjon .............. c c c c
12 skriv ned alle medisiner – både de med og uten 
resept – som du har brukt regelmessig i siste 4 ukers 
periode. (Ikke regn med vitaminer, mineraler, urter, 
naturmedisin, andre kosttilskudd etc.)
Ved fRAMMØte vil du bli spurt om du har brukt 
antibiotika eller smertestillende medisiner de siste  
24 timene. Om du har det, vil vi be om at du oppgir 
preparat, styrke, dose og tidspunkt
13 Hvem bor du sammen med? (Sett kryss for hvert 
spørsmål og angi antall) 
Ja Nei Antall
Ektefelle/samboer ............................................. c c
Andre personer over 18 år ........................ c c
Personer under 18 år ...................................... c c
14 Kryss av for de slektninger som har eller har hatt
Foreldre Barn Søsken
Hjerteinfarkt .............................................. c c c
Hjerteinfarkt før fylte 60 år ......... c c c
Angina pectoris (hjertekrampe) ...... c c c
Hjerneslag/hjerneblødning .......... c c c
Beinskjørhet (osteoporose)  ................ c c c
Magesår/tolvfingertarmsår .......... c c c
Astma .............................................................. c c c
Diabetes ........................................................ c c c
Demens .......................................................... c c c
Psykiske plager ........................................ c c c
Rusproblemer ........................................... c c c
15 Har du nok venner som kan gi deg hjelp  
når du trenger det?
c Ja c Nei
16 Har du nok venner som du kan snakke fortrolig med?
c Ja c Nei
17 Hvor ofte tar du vanligvis del i foreningsvirksomhet 
som for eksempel syklubb, idrettslag, politiske lag, 
religiøse eller andre foreninger?
c Aldri, eller noen få ganger i året
c 1-2 ganger i måneden
c Omtrent 1 gang i uken
c Mer enn en gang i uken
ARBEID, TRYGD OG INNTEKT
18 Hva er din høyeste fullførte utdanning?  
(Sett ett kryss)
c Grunnskole, framhaldsskole eller folkehøyskole
c Yrkesfaglig videregående, yrkesskole eller realskole 
c Allmennfaglig videregående skole eller gymnas
c Høyskole eller universitet, mindre enn 4 år
c Høyskole eller universitet, 4 år eller mer
FAMILIE OG VENNERBRUK AV MEDISINER
Får du ikke plass til alle medisiner, bruk eget ark.
25 Hvor ofte driver du mosjon? (Med mosjon mener vi 
at du f.eks går en tur, går på ski, svømmer eller driver  
trening/idrett)
c Aldri
c Sjeldnere enn en gang i uken
c En gang i uken
c 2-3 ganger i uken
c omtrent hver dag
36 Hvor mange år til sammen har du røykt daglig?
Antall år
35 Hvor gammel var du da du begynte å røyke daglig?
Antall år
22 Arbeider du utendørs minst 25 % av tiden, eller i 
lokaler med lav temperatur, som for eksempel  
lager-/industrihaller?
c Ja c Nei
23 Hvis du er i lønnet eller ulønnet arbeid, hvordan vil 
du beskrive arbeidet ditt?
c For det meste stillesittende arbeid
(f.eks. skrivebordsarbeid, montering)
c Arbeid som krever at du går mye
(f.eks ekspeditørarbeid, lett industriarbeid, undervisning)
c Arbeid der du går og løfter mye
(f.eks postbud, pleier, bygningsarbeider)
c Tungt kroppsarbeid
24 Angi bevegelse og kroppslig anstrengelse i din  
fritid. Hvis aktiviteten varierer meget f eks mellom 
sommer og vinter, så ta et gjennomsnitt. spørsmålet 
gjelder bare det siste året. (Sett kryss i den ruta som 
passer best)
c Leser, ser på fjernsyn eller annen stillesittende  
beskjeftigelse
c Spaserer, sykler eller beveger deg på annen måte 
minst 4 timer i uken (her skal du også regne med gang 
eller sykling til arbeidsstedet, søndagsturer med mer)
c Driver mosjonsidrett, tyngre hagearbeid, snømåking 
e.l. (merk at aktiviteten skal vare minst 4 timer i uka)
c Trener hardt eller driver konkurranseidrett  
regelmessig og flere ganger i uka
26  Hvor hardt mosjonerer du da i gjennomsnitt?
c Tar det rolig uten å bli andpusten eller svett.
c Tar det så hardt at jeg blir andpusten og svett
c Tar meg nesten helt ut
29 Hvor mange enheter alkohol (en øl, et glass vin, eller 
en drink) tar du vanligvis når du drikker?
c 1-2 c 5-6 c 10 eller flere
c 3-4 c 7-9
32 Har du røykt/røyker du daglig?
c Ja, nå c Ja, tidligere c Aldri
27 Hvor lenge holder du på hver gang i gjennomsnitt ?
c Mindre enn 15 minutter c 30 minutter – 1 time
c 15-29 minutter c Mer enn 1 time
30 Hvor ofte drikker du 6 eller flere enheter alkohol ved 
en anledning?
c aldri
c sjeldnere enn månedlig
c månedlig
c ukentlig
c daglig eller nesten daglig
28 Hvor ofte drikker du alkohol? 
c Aldri
c Månedlig eller sjeldnere
c 2-4 ganger hver måned
c 2-3 ganger pr. uke
c 4 eller flere ganger pr.uke
21 Hvor høy var husholdningens samlede bruttoinntekt 
siste år? Ta med alle inntekter fra arbeid, trygder, 
sosialhjelp og lignende.
c Under 125 000 kr c 401 000-550 000 kr
c 125 000-200 000 kr c 551 000-700 000 kr
c 201 000-300 000 kr c 701 000 -850 000 kr 
c 301 000-400 000 kr c Over 850 000 kr
34 Hvis du røyker daglig nå eller har røykt tidligere: 
Hvor mange sigaretter røyker eller røykte du vanlig-
vis daglig?
Antall sigaretter
33 Hvis du har røykt daglig tidligere, hvor lenge er det 
siden du sluttet?
Antall år 
31 Røyker du av og til, men ikke daglig?
c Ja c Nei
20 Mottar du noen av følgende ytelser?
c Alderstrygd, førtidspensjon (AFP) eller etterlattepensjon




c Dagpenger under arbeidsledighet
c Overgangstønad
c Sosialhjelp/-stønad 
37 Bruker du, eller har du brukt, snus eller skrå?
c Nei, aldri c Ja, av og til
c Ja, men jeg har sluttet c Ja, daglig
FYSISK AKTIVITET
ALKOHOL OG TOBAKK
48 Hvis du har født, fyll ut for hvert barn: fødselsår og 
vekt samt hvor mange måneder du ammet.  
(Angi så godt som du kan)









39 Hvor mange enheter frukt og grønnsaker spiser du i 
gjennomsnitt per dag? (Med enhet menes f.eks. en 
frukt, glass juice, potet, porsjon grønnsaker)
Antall enheter
38 spiser du vanligvis frokost hver dag?
c Ja c Nei
40 Hvor mange ganger i uken spiser du varm middag? 
Antall
42 Hvor mye drikker du vanligvis av følgende?  















yoghurt .......................... c c c c c
Fruktjuice ...................... c c c c c
Brus/leskedrikker 
med sukker ................. c c c c c
44 Hvor ofte spiser du vanligvis fiskelever? 
(For eksempel i mølje)
c Sjelden/aldri c 1-3 g i året c 4-6 g i året































45 Bruker du følgende kosttilskudd?
Daglig Iblant Nei
Tran, trankapsler ..................................................... c c c
Omega 3 kapsler (fiskeolje,selolje) ............ c c c
Kalktabletter ............................................................ c c c
47 Hvor mange barn har du født?
Antall
49 Har du i forbindelse med svangerskap hatt for høyt  
blodtrykk?
c Ja c Nei
52 Hvis Ja, i hvilket svangerskap?
c Første c Senere
53 Ble noen av disse barna født mer enn en måned for 
tidlig (før termin) pga. svangerskapsforgiftning?
c Ja c Nei
55 Hvor gammel var du da du fikk menstruasjon  
første gang?
Antall år
51 Har du i forbindelse med svangerskap hatt protein  
(eggehvite) i urinen?
c Ja c Nei
50 Hvis Ja, i hvilket svangerskap? 
c Første c Senere
54 Hvis Ja, hvilke(t) barn
Barn 1 Barn 2 Barn 3 Barn 4 Barn 5 Barn 6
c c c c c c
43 Hvor mange kopper kaffe og te drikker du daglig? 






56 Bruker du for tiden reseptpliktige legemidler som 
påvirker menstruasjonen?
P-pille, hormonspiral eller lignende .......c Ja c Nei
Hormonpreparat for overgangs-
alderen .............................................................................c Ja c Nei
46 er du gravid nå?
c Ja c Nei c Usikker
Ved fRAMMØte vil du få utfyllende spørsmål om 
menstruasjon og eventuell bruk av hormoner. Skriv 
gjerne ned på et papir navn på hormonpreparater 
du har brukt, og ta det med deg. Du vil også bli 
spurt om din menstruasjon har opphørt og even-
tuelt når og hvorfor.
41 Hvor ofte spiser du vanligvis disse matvarene?
(Sett ett kryss pr linje)










Poteter ........................................ c c c c c
Pasta/ris ..................................... c c c c c
Kjøtt (ikke kvernet) ................ c c c c c
Kvernet kjøtt  
(pølser, hamburger o.l) ........... c c c c c
Grønnsaker, frukt, bær .. c c c c c
Mager fisk ............................... c c c c c
Feit fisk ....................................... c c c c c
(f.eks.laks, ørret, makrell, sild, kveite,uer)
KOSTHOLD SPØRSMÅL TIL KVINNER
